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The traditional experimental approaches used for changing the ﬂux or the concentration of a particular metabolite of a metabolic
pathway have been mostly based on the inhibition or over-expression of the presumed rate-limiting step. However, the attempts
to manipulate a metabolic pathway by following such approach have proved to be unsuccessful. Metabolic Control Analysis
(MCA) establishes how to determine, quantitatively, the degree of control that a given enzyme exerts on ﬂux and on the
concentration of metabolites, thus substituting the intuitive, qualitative concept of rate limiting step. Moreover, MCA helps to
understand (i) the underlying mechanisms by which a given enzyme exerts high or low control and (ii) why the control of the
pathway is shared by several pathway enzymes and transporters. By applying MCA it is possible to identify the steps that should
be modiﬁed to achieve a successful alteration of ﬂux or metabolite concentration in pathways of biotechnological (e.g., large
scale metabolite production) or clinical relevance (e.g., drug therapy). The diﬀerent MCA experimental approaches developed
for the determination of the ﬂux-control distribution in several pathways are described. Full understanding of the pathway
properties when is working under a variety of conditions can help to attain a successful manipulation of ﬂux and metabolite
concentration.
Copyright © 2008 Rafael Moreno-S´ anchez et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Is an eﬀort to manipulate the metabolism of an organism
worthyandreasonable,knowingthatthiscellularprocesshas
been continuously modiﬁed and reﬁned through evolution
and natural selection for adapting, in the most convenient
manner, to the ongoing environmental conditions? The
answer to this question seems obvious when three broad
areas of research and development are identiﬁed in which
manipulation of metabolic pathways is relevant: (a) drug
design to treat diseases, (b) genetic engineering of organisms
of biotechnological interest, and (c) genetic syndromes
therapy.
Historically, drug design was the ﬁrst area in which
modiﬁcation of metabolism was tried: the primary goal of
drug administration is the inhibition of essential metabolic
pathways,forexample,inaparasiteoratumorcell.Thus,any
metabolic pathway can be a potential therapeutic target. In
the absence of a solid theoretical background that may build
astrategyfortherationaldesignofdrugs,thepharmaceutical
industry has applied the knowledge of inorganic and organic
chemistry for the arbitrary and rather randomized modi-
ﬁcation of metabolic intermediaries by replacing hydrogen
atoms in a model molecule with any other element or
compound. This approach has been successful in the battle
against many diseases. However, in many other instances
such an approach has been unsuccessful.
The era of rational drug design probably started in
the 50s when Hans Krebs proposed that, after having an
exact description of a metabolic pathway, the “pacemaker”
enzyme or “rate-limiting step” had to be identiﬁed. This
approach certainly decreased the amount of intermediaries
to be chemically modiﬁed, focusing only on the substrates,
products, and allosteric eﬀectors of the “rate-limiting step,”
instead of dispersing eﬀorts on all the metabolic pathway
intermediates. The experimental approaches used in the2 Journal of Biomedicine and Biotechnology
identiﬁcation of the pacemaker, key enzymes, “bottlenecks.”
limiting steps, or regulatory enzymes [1, 2]w e r e
(i) inspectionofthemetabolicpathwayarchitecture:due
to cell economy and for reaching the highest eﬃ-
ciency, pathway control must reside in the enzymes
localized at the beginning of a pathway or after a
branch (teleological approach);
(ii) determination of nonequilibrium reactions: those
reactions in which the quotient between the mass
action ratio (Γ) and its equilibrium constant (Keq)
is low, Γ/Keq   1 (thermodynamic approach);
(iii) identiﬁcation of the steps with the lowest maximal
rates (Vmax) in cellular extracts: the key enzyme of
thepathwayistheonethathasthelowestrate(kinetic
approach);
(iv) enzymes with sigmoidal kinetics: steps that are
susceptible to alteration in their kinetic properties by
compounds diﬀerent from substrates and products
and which may coordinate the entire metabolism
(NADH/NAD+; NADPH/NADP+,A T P / A D P ;a c e t y l
CoA/CoA; Ca2+/Mg2+; high pH/low pH) or at least
two metabolic pathways (citrate, Pi, AMP, malonyl-
CoA);
(v) crossover theorem. Comparing the intermediary
concentrations between a basal and an active steady-
state pathway ﬂux, the rate-limiting step in the basal
condition will be that for which its substrate con-
centration diminishes and its product concentration
increases when the system changes from the basal to
the active state or vice versa (crossover point on a
histogram of each intermediary versus its normalized
variation in concentration);
(vi) the shape of the metabolic ﬂux inhibition curve: a
sigmoidal curve on a plot of inhibitor concentration
versus ﬂux shows that the sensitive step to the
inhibitor exerts no control, that is, there is not
proportionality between enzyme activity inhibition
and pathway ﬂux inhibition because there is an
“excess” of enzyme. On the other hand, a hyperbolic
curve indicates that the enzyme susceptible to the
inhibitor controls the ﬂux.
2. CONTROLLINGSITES IN A METABOLIC PATHWAY
Once a site in a metabolic pathway has been identiﬁed with
at least one of the criteria described above as “the rate-
limiting step,” researchers have frequently concluded that
such enzyme or transporter is the only limiting step of the
metabolicﬂuxandextendthisconclusiontoallcelltypesand
to all conditions.
For example, inspection of the glycolytic pathway (tele-
ological approach) suggests that hexokinase (HK) and
phosphofructokinase-1 (PFK-1) (which are at the beginning
and after a branch of the pathway) are the key steps of
glycolysis. However, all studies on glycolysis in the 60s,
70s, and 80s were performed by taking into account only
the intracellular reactions from HK to LDH (i.e., without
including the glucose transport reaction through the plasma
membrane) and by considering glycolysis as a linear pathway
without branches. To this regard, it is recalled that the
glucose transporter (GLUT) includes a family of proteins
and genes that are susceptible of regulation. Thus, if the
extracellular glucose is considered as the initial glycolytic
substrate, then another potential key step would be GLUT.
Hence, if all the branches of the pathway are considered
(Figure 1), then according to the teleological approach there
will be additional potential rate-limiting sites.
Applicationofthethermodynamicandkineticapproach-
es to glycolysis reveals that HK, PFK-1, and pyruvate kinase
(PYK) are the rate-limiting steps because in the living cell
they catalyze reactions that are far away from equilibrium
(Γ/Keq = 10
−3–10
−4), and they are also the slowest enzymes
in the pathway by at least one order of magnitude (they have
the lowest Vmax values).
The use of the enzyme cooperativity approach has
established that the regulatory steps of glycolysis are (i)
PFK-1 and PYK because they are allosteric enzymes and
(ii) HK because it is inhibited by its products (G6P and
ADP, or AMP as an ADP-analogue). The application of
the crossover theorem (approach no. v) to glycolysis has
shown a consistent variation in the PFK-1 substrate (F6P)
and product (F1,6BP). Up to now, there are few studies
on control of glycolysis using the shape of the inhibitor
titrating curve (approach no. vi), due to the lack of speciﬁc
inhibitors for any of the three presumed key steps. An
exception is iodoacetate which is indeed a potent inhibitor
of GAPDH, but also of other highly reactive cysteine-
containing enzymes [3–5]. By using iodoacetate as speciﬁc
inhibitor, both GAPDH activity and ﬂux showed identical
titration curves, leading to the conclusion that GAPDH
was the rate-limiting step of glycolysis in Streptococcus lactis
and S. cremoris [6] (see, however, Section 3.2; Glycolysis in
lactobacteria below).
All together, these results constitute the main reason
why many intermediary metabolism researchers, including
the authors of biochemistry text books, have proposed HK,
PFK-1, and PYK as the rate-limiting steps of glycolysis. In
consequence,tovarytheglycolyticﬂux,oneoftheseenzymes
h a st ob em o d i ﬁ e d .
Although the above-described experimental approaches
are qualitative, full control has been automatically assigned
to the “key” steps because the concept of the rate-limiting
step assumes that there is only one single enzyme controlling
the metabolic pathway ﬂux (and the concentration of the
ﬁnal product of the pathway) and, in consequence, assigns
valuesofzerotothecontrolexertedbytheotherenzymesand
t r a n s p o r t e r s .H o w e v e r ,a sa n a l y z e df o rg l y c o l y s i s ,r e s e a r c h e r s
have commonly “identiﬁed” more than one limiting step.
In the case of oxidative phosphorylation (OXPHOS), in
the 70s and 80s some researchers considered cytochrome c
oxidase as the rate-limiting step, whereas others preferred
the ATP/ADP translocator or the Krebs cycle Ca2+-sensitive
dehydrogenases (for a review, see [7]).
Rephrasing the initial question, which could be the aim
of manipulating a metabolic pathway such as glycolysis,Rafael Moreno-S´ anchez et al. 3
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Figure 1: Glycolytic pathway and principal branches. GLUT, glucose transporter; HK, hexokinase; PFK-1, phosphofructokinase-1; G6P,
glucose-6-phosphate; F1,6BP, fructose 1,6 bisphosphate; DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde-3-phosphate; 3PG,
3-phosphoglycerate; PEP, phosphoenolpyruvate; pyr, pyruvate; PYK, pyruvate kinase; L-lac, L-lactate; acetal, acetaldehyde; AT, alanine
transaminase. S. cerevisiae lacks the LDH gene.
knowing its universal distribution in the living organisms?
From a clinical standpoint, the inhibition of glycolysis is
relevant for the treatment of human parasitic or patho-
logical diseases such as cancer. The glycolytic reactions are
almost identical in all organisms; in addition, the enzymes
catalyzing these reactions are highly conserved throughout
the evolutionary scale (their amino acid sequences are highly
similar). In mammals, the genes of the 12 glycolytic enzymes
are scattered throughout the genome, generally in diﬀerent
chromosomes, whereas in bacteria many of the glycolytic
enzymes are clustered in operons [8]. However, there are
organisms(likesomehumanparasites)thatcontainenzymes
with remarkable diﬀerences in their biochemical proper-
ties (substrate selectivity, catalytic capacity, stability, and
oligomeric structure), or in genetic expression regulation in
comparison to the human enzymes, which could be consid-
ered as drug targets.
Furthermore, some glycolytic products are of commer-
cial interest such as ethanol for wine, beer, and other
alcoholic beverages; CO2 for bread manufacturing; and
lactic acid and other organic acids for cheese production.
Thus, from a biotechnological standpoint, it is convenient
to accelerate the pathway ﬂux to diminish the processing
time and it is also desirable to increase the concentration of
the metabolite to obtain robust commercial products. Here,
it is important to emphasize that the metabolic pathways
are designed to attain changes in ﬂux with minimal dis-
turbances in the intermediary concentrations. For example,
the glycolytic ﬂux in skeletal muscle can increase from rest
to an active state by 100 fold, without large changes in4 Journal of Biomedicine and Biotechnology
Table 1: Overexpression of glycolytic enzymes in diﬀerent cell types.
Cell type Enzyme Activity
(overexpression fold)
Flux (% Control) Reference
Saccharomyces
cerevisiae
HK 13.9 107 [12]
PFK-1 3.5, 3.7,5 102 [9, 10, 12]
PYK 8.6 107 [12]
PDC 3.7 85 [13]
ADH 4.8 89 [12]
PFK-1 + PYK 5.6 + 1.3 107 [12]
GAPDH + PGK +
P G A M+E N O+P Y K
+P D C+A D H
1.4 + 1.7 + 16 + 4 +
10.4 + 1.08 + 1.4
121 [12]
GAPDH + PGK +
P G A M+E N O+P Y K
+P D C+A D H
1.5 + 1.4 + 3.4 + 1.5 +
2.5 + 1.1 + 1.2
94 [11, 14]
Escherichia coli PFK 8.7 72 [15]
PYK 2.9, 4.2 91,95 [16]
Lactococcus lactis GAPDH 14-210 100 [17]
Aspergillus niger PFK 3 100
[18] PYK 5 100
Chinese hamster ovary PFK 2.2, 3.4, 3.7 100 [19]
Flux to ethanol was for S. cerevisiae and E. coli; ﬂux to citrate was for A. niger; and ﬂux to L-lactate was for hamster.
metabolites. Then, it is physiologically more common to
change a metabolic ﬂux and the production of the ﬁnal
metabolite in the pathway than varying the intermediary
concentrations [2]. However, we will see that, by using a
suitable approach of metabolic control analysis, it is possible
to design strategies to manipulate not only ﬂuxes but also
metabolic intermediary concentrations.
3. IN VIVO OVEREXPRESSION EXPERIMENTS
OF ENZYMES
3.1. Glycolysisinyeasts
When the yeast Saccharomyces cerevisiae is exposed to high
glucose (>2%; 0.11M), the genes of all glycolytic enzymes
are induced (PDC and ENO increase their expression by 20
fold; PGK, PYK, and ADH, 3–10 times; and the others, 2
fold in average) [8–11]. However, when the methodological
development of genetic engineering allowed modulating the
expression of enzymes within cells, researchers turned to the
rate-limiting step concept to manipulate a metabolic path-
way to increase ﬂux and/or its intermediates, hypothesizing
that the overexpression of only one, or of a few key glycolytic
genes, should increase the ﬂux.
Historically,Heinisch[9]inGermanywastheﬁrstauthor
to obtain a 3.5 fold overexpression of PFK-1 in S. cerevisiae,
but surprisingly he observed that the rate of ethanol
production was not modiﬁed. Subsequent experiments for
increasing the ethanol production rate by overexpressing
eithereachofthepresumedlimitingsteps,orincombination
with other glycolytic enzymes (Table 1), have been unsuc-
cessful and, even in some cases, a slight decrease in ﬂux has
been attained. For instance, the simultaneous overexpression
of seven enzymes of the ﬁnal section of glycolysis induced
only a 21% increase in ethanol production after 2 hours of
culture (Table 1)[ 11]. This was accompanied by a 10–20%
decrease in PFK-1 expression, which might have attenuated
the ﬂux increase.
In yeasts, HK is not product inhibited by G6P or ADP;
instead, it is strongly feedback inhibited by trehalose-6-
phosphate (Tre6P). This metabolite is synthesized from G1P
by Tre6P synthase and Tre6P phosphatase. Deletion of the
Tre6P synthase gene does not bring about an increased
ethanol production, but it rather induces a defective cellular
growth on glucose and fructose and a lowered ethanol
production, as a result of a highly active HK that leads to
hyperaccumulationofhexosephosphatemetabolites(partic-
ularlyF1,6BP)andfastdepletionofATP,Pi,anddownstream
metabolites. The explanation for this event is that, in the
Tre6P synthase mutants, the rate of glucose phosphorylation
exceeds the rate of glycolytic ATP synthesis (named “turbo
eﬀect”). Heterologous expression of a Tre6P-insensitive
HK does not recover completely the wild-type phenotype.
Furthermore, deletion of the Tre6P synthase gene in the
Tre6P-insensitive HK strain did aﬀect growth, suggesting
other interactions and functions of Tre6P synthase in the
control of sugar metabolism, at least in Schizosaccharomyces
pombe [20].
Davies and Brindle [10] obtained a 5-fold overexpression
of PFK-1 in S. cerevisiae, but the increase in ethanol
production was not attained under anaerobic conditions.
There was a slight increase in ethanol production in resting
cells in aerobic conditions, under which the mitochondrial
metabolismcontributestotheATPsupply.Inalltheseworks,Rafael Moreno-S´ anchez et al. 5
it may be noted that enzyme overexpression indeed aﬀects
theconcentrationofseveralintermediaries,butthiseﬀecthas
not been further examined.
It is worth noting that the experiments described in
Table 1 do not rigorously reproduce the physiological situ-
ation, in which overexpression of all the enzymes should be
carried out in the proportions found in the organisms. The
rationale behind this observation is that overexpression of
onlyone“limiting”stepleadstoaﬂuxcontrolredistribution,
a condition at which other steps now become rate limiting.
Thus, the concept of “rate-limiting step” oﬀers no simple
answer to the question of increasing the yeast glycolytic
ﬂux, and it rather makes this problem to appear as a
diﬃcult task to solve. In contrast, it seems that all relevant
controlling steps have to be overexpressed, thus reproducing
what natural selection has already successfullyaccomplished.
In addition to S. cerevisiae, overexpression of glycolytic
enzymes in other organisms such as E. coli [15, 16],
lactobacteria [17], tomato [21], potato [22], and hamster
ovary cells [19] has been accomplished, although without
increasing ﬂux (Table 1). It is somewhat surprising to note
that in the glycolytic enzyme overexpression experiments,
the strong inhibitory eﬀect of G6P (or Tre6P in S. cerevisiae),
and citrate on HK and PFK-1, respectively, have been
neglected. This regulatory mechanism does not disappear in
thecellsoverexpressingtheenzymesbut,onthecontrary,itis
exacerbated. Then, what would be the aim of overexpressing
HK, PFK-1 or any other allosteric, or strongly product-
inhibited enzyme if they will be more inhibited?
A successful experiment of increasing the glycolytic ﬂux
was performed in primary cultures of rat hepatocytes [23].
HK and glucokinase (GK) were overexpressed by using
adenovirus as carrier. The transformed hepatocytes showed
higher activity of 18.7- and 7.1-times for HK and GK,
respectively, at 3mM glucose, and of 6.3- and 7.1-times
at 20mM glucose. However, at 20mM glucose, the ﬂux to
lactate was not modiﬁed in HK-transformed cells, just like
the experiments described above (Table 1). In contrast, with
GK overexpression, a 3-fold increase in ﬂux was achieved.
The mechanistic diﬀerence is the HK inhibition by G6P
(10mM G6P inhibits HK activity by 90%), whereas GK is
not product inhibited.
3.2. Glycolysisinlactobacteria
Lactococcus lactis is used in cheese production. For this
purpose, L. lactis ferments lactose to lactic acid by glycolysis.
The end products, lactate and H+, are expelled and acidify
the external medium which contributes to cheese ﬂavor and
texture and inhibits the growth of other bacteria. Similarly
to yeast, the lack of carbon source in lactobacteria promotes
a metabolic change that leads to the production of formic
and acetic acids, ethanol, and, in a lower proportion, L-lactic
acid, altering the product quality. Thus, from a commercial
point of view, it does not seem important to know what
controls the ﬂux to lactate (because its rate of production is
adequate), but what controls the branching ﬂux.
To understand the process, and to eventually inhibit
the production of secondary acids, Andersen et al. [24]
constructed LDH mutants, using a synthetic promoter
library for tuning the gene expression. In mutants lacking
this enzyme, most of the pyruvate was transformed into
acetic and formic acids (Figure 1). In turn, ﬂux to lactate was
aﬀected in mutants expressing only 10% or less of wild-type
LDH levels, which indicated that LDH exerts no control of
the glycolytic ﬂux in wild-type bacteria. Only with a normal
content of this enzyme (100%), ﬂux toward secondary acids
was prevented. Therefore, the ﬂux to formic and acetic acids
is negatively controlled by LDH, and positively by PYK
[17, 25]. As in S. cerevisiae, overexpression of PFK-1, PYK, or
GAPDH in lactobacteria did not increase the ﬂux to L-lactic
acid [17, 25]. Similarly to E. coli glycolysis [26], glycolysis in
L. lactis was controlled by the ATP demand when working
below its maximum capacity [27, 28], whereas, under
high-rate conditions, the glucose and lactate transporters
exerted the main ﬂux control [28]. Furthermore, this kind
of observations indicates that the ﬂux control may reside
outside the pathway [27–29], and it also supports the
proposal by Hofmeyr and Cornish-Bowden [30] that the
end-product demand (which is usually overlooked in studies
of metabolism because these metabolites are frequently not
considered as part of the pathway) might be essential in ﬂux
control.
3.3. Glutathioneandphytochelatinsynthesisinplants
Glutathione (γ-Glu-Cys-Gly; GSH) is the most abundant
nonproteinaceous thiol compound (1–10mM) in almost
all living cells. GSH is involved in the oxidative stress
processing, xenobiotic detoxiﬁcation, and, in some plants
and yeasts, in the inactivation of toxic heavy metals (for
a recent revision see [31]). GSH is synthesized by two
enzymes: γ-glutamylcysteine synthetase (γ-ECS) and glu-
tathione synthetase (GS) (Figure 2), which catalyze reactions
with high-equilibrium constants (Keq > 1000). Under a
low GSH demand (unstressed conditions), the producing
block of enzymes has to receive information from the last
part of the pathway to (i) avoid the excessive and toxic
accumulation of the intermediary γ-EC and (ii) reach a
stablesteadystate[32].Thisinformationtransferismediated
by GSH, which exerts strong competitive inhibition of γ-
ECS [33]( Figure 2). GSH and Cys also exert inhibition
on the ATP-sulfurylase (ATPS) and on sulfate transporters
(Figure 2)( f o rar e v i e w ,s e e[ 31]). The feedback inhibition
of γ-ECS has led several researchers to propose that this
enzyme is the rate-limiting step of GSH synthesis [33–35].
Although there are no studies about the pathway’s behavior
under stressed conditions, which means under a high GSH
demand, the proposal that γ-ECS is the key enzyme has been
automatically extended to any environmental condition such
as heavy metal exposure.
By assuming that γ-ECS is the rate-limiting step, many
research groups have tried to increase, in plants and yeasts,
the rate of synthesis and the concentration of GSH and
phytochelatins (PCs) with the aim of fortifying their heavy
metal resistance and storage capacity, mainly toward Cd
2+.
The development of organisms able to grow in soils and
water systems contaminated with heavy metals, which may6 Journal of Biomedicine and Biotechnology
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Figure 2: Sulfur assimilation and glutathione and phytochelatins synthesis in plants ATPS, ATP sulfurylase; APS, adenosine 5 
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Modiﬁed from [31].
have the ability of accumulating toxic metal ions, is of
biotechnological interest for bioremediation strategies.
With this goal in mind, researchers have then over-
expressed γ-ECS and other pathway enzymes, including
phytochelatin synthase (PCS) (Table 2). Some of these
experiments have been partially successful in increasing
GSH levels, although this has been rather marginal with no
correlation between enzyme levels and GSH concentration.
Unfortunately, these overexpression experiments have not
been accompanied by determinations of ﬂuxes or other
relevant metabolite concentrations such as PCs or Cys. On
the other hand, the overexpression of PCS has surprisingly
induced oxidative stress and necrosis instead of increasing
Cd
2+ accumulation and resistance [36]. This result suggests
that, under high GSH demand (i.e., for PCs synthesis and
for direct heavy metal sequestration by GSH), the GSH
concentration does not suﬃce for maintaining the other
essentialGSHfunctionssuchasoxidative stressmanagement
and xenobiotic detoxiﬁcation.
Another problem in the study of GSH biosynthesis for its
eventual manipulation is that the pathway has been analyzed
considering onlytheGSH-synthetic reactionswithouttaking
into account the GSH-consuming reactions (Figure 2), [31].
The analysis of an incomplete pathway leads to misleading
conclusions about the control of ﬂux. Metabolic modeling
hasshownthatonlywiththeincorporationoftheconsuming
reactions of the pathway end products, a true steady state can
be established [30]. In conclusion, without a solid theoreticalRafael Moreno-S´ anchez et al. 7
Table 2: GSH and phytochelatin synthesis enzymes overexpression in plants and yeasts.
Overexpressed enzyme
(activity fold)
Organism (experimental
condition)
Metabolite
Reference
(increment fold)
ATP sulfurylase (2.1) Brassica juncea 2.1 [GSH] [37]
ATP sulfurylase (4.8) Tobacco (unstressed) 1.3 [SO4
2−] [38]
O-acetyl-serine thiol-lyase
(2.5) Tobacco (unstressed)
2[ C y s ]
[39]
0[ G S H ]
Serine acetyl transferase
(>10)
Potato chloroplasts
(unstressed)
2[ C y s ]
[40]
0[ G S H ]
E. coli GS (90) Populus tremula
(unstressed)
0[ G S H ] [34]
GS (3) S. cerevisiae (unstressed) 0[ G S H ] [41]
E. coli γ-ECS (>2)
Brassica juncea
(unstressed)
0[ G S H ]
[35]
B. juncea (+100μMC d
2+) 4[ G S H ] (a)
γ-ECS (2.1) S. cerevisiae (unstressed)) 1.3 [GSH] [42]
E. coli γ-ECS (50) Populus tremula
(unstressed)
4.6 [GSH] [34]
E. coli γ-ECS (4.9)
Brassica juncea
(unstressed) B. juncea
(+200μMC d
2+)
3.5 [GSH](b)
[43]
1.5 [GSH](b)
E. coli γ-ECS (40) Tobacco (unstressed) >4[ G S H ] [44]
γ-ECS (9.1) + GS (18) S. cerevisiae (unstressed) 1.8 [GSH] [45]
PCS (>2) Arabidopsis thaliana
(+85μMC d
2+)
0[ G S H ] [36]
Vacuolar transporter of
PC-Cd complexes (>2) S. pombe
Higher Cd
2+
[46]
resistance
(a)The increase was only in roots with no eﬀect on shoots. (b)The increase was only in shoots with no eﬀect on roots.
framework, the overexpression of only one enzyme (the
“rate-limiting step”), or of many arbitrarily selected enzymes
(Tables 1 and 2), the problem of increasing the ﬂux or
metabolite concentrations cannot be solved.
3.4. Overexpressionofproteinsfromother
metabolicpathways
There are some successful examples of the genetic engineer-
ing approach to manipulate metabolism:
(i) overexpression (approx. 23 fold) of the ﬁve genes of
the tryptophan synthesis pathway in S. cerevisiae,t o
increase (9-fold) ﬂux [47];
(ii) increase in amino acids (Trp, Ile, Lys, Val, Thr)
and trehalose production in Corynebacterium glu-
tamicum, in which some proteins of each metabolic
pathway are simultaneously overexpressed, but some
of them with mutations that confer insensitivity to
feedback inhibition [48–53]. In these transformed
bacteria, the end products are indeed overproduced
and their excretion is accelerated;
(iii) overexpression of PFK and PyK to increase ethanol
production by 35% in E. coli, although lactic acid
formation was not modiﬁed [16];
(iv) mannitol 1-phosphate dehydrogenase and mannitol
1-phosphatase overexpression to increase mannitol
production by 27–50% in LDH-deﬁcient Lactococcus
lactis [54];
(v) increase in sorbitol production (5 fold) in LDH-
deﬁcient Lactobacillus plantarum through the over-
expression of sorbitol 6-phosphate dehydrogenase
(activity up to 250 fold in mutants versus wild type)
[55];
(vi) overexpression of PFK (14 fold) or LDH (3.5 times)
to increase 2-3 times the homolactic fermentation
ﬂux in Lactococcus lactis growing on maltose, and in
parallel decrease ﬂuxes toward secondary acids and
ethanol [56].
4. DOWNREGULATION OF ENZYMES TO
MANIPULATE METABOLISM
4.1. Glycolysisintumorcells
Glycolysis is enhanced in human and animal cancer cells
(reviewed in [57]). Several glycolytic enzymes are overex-
pressedinatleast70%ofhumancancers[58].Exceptforglu-
cosetransporter1(GLUT-1),theother11glycolyticenzymes
(HK to LDH) are overexpressed in brain and nervous system
cancers. Prostate and lymphatic nodule cancers (Hodgkin
and non-Hodgkin lymphomas; myelomas) overexpress 10
glycolyticenzymes(exceptforHK;inprostatecancerGLUT18 Journal of Biomedicine and Biotechnology
2-Glu + 2-Cys
2ATP-Mg2+
2ADP-Mg2+
2ATP-Mg2+
2ADP-Mg2+
γ-ECS
2γ-EC
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2-GSH
Ornithine
ODC
CO2
Putrescine
S-adenosyl-
L-methionine
PAT
Spermidine
2ADP-Mg2+
2ATP-Mg2+
TryS
Trypanothionered
Glyoxalase system
Metal/drug
detoxiﬁcation
APX
TXNPx
GPX I
GPX II
H2O
H2O2
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H2O2
ROH
ROOH
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DHA
TPXox
TPXred
GSSG
GSH
Thiol
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TryR
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Figure 3: Trypanothione synthesis in trypanosomatids. The trypanothione producing enzymes are γ-ECS, GS, ODC, aminopropyl
transferase (PAT), and TryS. The trypanothione consuming enzymes are ascorbate peroxidase (APX); tryparedoxin peroxidases (TXNPx);
trypanothione-glutathione thiol transferase (thiol transferase); and glutathione peroxidases I (GPX I) and II (GPX II). The regenerating
enzyme is TryR. APX, thiol transferase, and GPX II have only been described in T. cruzi. This last parasite lacks ODC activity, but it has
developed high-aﬃnity transporters for putrescine, cadaverine, and spermidine [71].
isalsooverexpressed).Thereisasecondgroupofcancersthat
overexpresses 6–8 glycolytic genes (skin, kidney, stomach,
testicles, lung, liver, placenta, pancreas, uterus, ovary, eye,
headandneck,andmammarygland).Athirdgroupincludes
those cancers overexpressing 1 or 2 glycolytic genes (bone,
bone marrow, cervix, and cartilage) [58].
In animals, gene expression of glycolytic enzymes is reg-
ulated (both coordinately and individually) under hypoxic
conditions by hypoxia-responsive transcription factors such
as HIF-1α (hypoxia-inducible factor 1α), SP family factors,
AP-1, and possibly MRE (metal response elements) [8, 59–
61]. HIF-1α is probably the principal coordinator in gene
induction. There are binding sites (consensus sequence
ACGT) for HIF-1α in the promoters of genes for HK
[62], PFK-1, ALDO, GAPDH, PGK, ENO, PYK, and LDH
(reviewed in [8] ) .T P Ia n dp e r h a p sH P Ia n dP G A Ma r e
also induced by hypoxia, but it is not clear whether HIF-
1α mediates this induction [8], and whether this factor
regulates other metabolic pathways associated with glucose
catabolism. For example, although glycogen phosphorylase
is overexpressed under hypoxia in human tissues [63], the
role of HIF-1 has not been demonstrated.
If direct manipulation of pathway genes becomes diﬃ-
cult, then the overexpression or repression of transcription
f a c t o r ss u c ha sH I F - 1 α, AP1, and MREs might solve the
problem of changing ﬂux, although overexpression of tran-
scription factors may also be diﬃcult due to the numerous
upstream and downstream factors involved.
4.2. GlycolysisinTrypanosomabrucei
The kinetoplastid parasites Trypanosoma cruzi, Trypanosoma
brucei, and Leishmania are the causative agents of Chagas
disease, African trypanosomiasis, and leishmaniasis, respec-
tively. The available drugs to treat these diseases are highly
toxic for humans. Moreover, the parasites may become
resistant,andhencethesearchfornewdrugsanddrugtargets
is relevant for solving these public health problems.
In these parasites, the metabolism is organized in a pecu-
liar way; they have a subcellular structure called glycosomeRafael Moreno-S´ anchez et al. 9
in which several metabolic pathways take place: gluconeo-
genesis, reactions of the pentose phosphate pathway, purine
salvage and pyrimidine biosynthesis, β-oxidation of fatty
acids, fatty acid elongation, biosynthesis of ether lipids, and
the ﬁrst seven steps of glycolysis. In fact, approximately
90% of glycosome enzyme content corresponds to glycolytic
enzymes [64]. Glycosomal glycolytic enzymes have unique
structural, kinetic, and regulatory features not found in their
human counterparts, and therefore have been the subject of
extensive biochemical studies to use them as drug targets
[65].Therationalebehindthisistosynthesizeinhibitorsthat
aﬀect mainly the parasitic enzymes with relatively low eﬀect
on the human enzymes since the infective parasite stages rely
mostly on glycolysis for ATP supply.
There are reports on the design of presumed speciﬁc
inhibitorsforsomeoftheT. brucei glycolyticenzymes:GLUT
(bromoacetyl-2-glucose) [66] ,H K ,H P I ,P F K ,A L D O ,T P I ,
GAPDH, PGK, PYK, and glycerol-3-phosphate dehydroge-
nase [67]. Although the puriﬁed enzymes display very low Ki
values for these inhibitors and some of them inhibit parasite
growth or infective capabilities, their eﬀect on inhibiting the
glycolytic ﬂux has not been explored. Therefore, it is not yet
possible to directly ascribe the eﬀects seen in parasite culture
with the in vitro eﬀects on the isolated enzymes. To identify
the best drug targets, determination of the ﬂux control steps
of glycolysis in T. brucei has been recently initiated [68].
4.3. Trypanothionesynthesisin
kinetoplastidparasites
Trypanothione (TSH2) is a reducing agent present in try-
panosomatids that is synthesized from one spermidine and
two GSH molecules by TSH2 synthetase (TryS) (Figure 3).
This metabolite and its reducing enzyme, TSH2 reductase
(TryR), replace the antioxidant and metabolic functions of
the more common GSH/GSH reductase system present in
mammals. In fact, most of the antioxidant metabolism of
these parasites depend on TSH2 (Figure 3)[ 69, 70]. Thus,
the enzymes of this metabolic pathway have been proposed
as drug targets for killing the parasites.
Several studies have focused in assessing TryR as drug
target. Diminution in its gene transcription yields a loss
of activity between 56–90%, depending on the genetic
technique [72–75]. In knockdown T. brucei cells (i.e., when
TryR activity has diminished to less than 10% of the wild-
type level),theparasitesshow growthdiminution andhigher
sensitivity to H2O2 in culture and loss of infectiveness in
mic e.H o wev er ,TSH 2 andthiolcompoundcontentswerenot
aﬀected [75]. TryR downregulation by >85% in Leishmania
species causes inability to survive under oxidative stress
inside macrophages [72–74]. In contrast, when TryR is
14- and 10 fold overexpressed in Leishmania and T. cruzi,
respectively, there are no signiﬁcant diﬀerences in H2O2
susceptibility between control and transfected cells; both
types of cells are also equally resistant to the oxidative
stress-inducers gentian violet, and nitrofurans [76]. Intrigu-
ingly, the cellular levels of TSH2, GSH, and glutathionyl-
spermidine, determined in both types of experiments (TryR
suppression and overexpression) were similar in control and
transformed cells.
Other studies have proposed TryS as an alternative
drug target. Knockdown of TryS by siRNA in procyclic
T. brucei causes (i) viability impairment and arrest of
proliferation when TSH2 levels decrease to 15% of the
wild-type level, (ii) increased sensitivity to H2O2 and alkyl
hydroperoxides, (iii) damage to the plasma membrane, and
(iv) diminution of the TSH2 content and accumulation of
GSH and glutathionyl-spermidine [77]. A similar metabolite
variation (lower TSH2; higher GSH) was attained with a
TryS knockdown induced by siRNA in the bloodstream form
of T. brucei [78]. This TryS knockdown also induced an
increasedsensitivitytodiﬀerentcompoundsthataﬀectTSH2
metabolism such as arsenicals, melarsen oxide, trivalent
antimonials, and nifurtimox [78]. Indeed, western blot
analysis showed, in addition to the expected (10-fold)
decrease in TryS protein, a 2-3-folds increase in γ-ECS
and TryR. The changes in expression of other enzymes
suggest unveiled compensatory or pleiotropic eﬀects on
TSH2 metabolism.
Other researchers have selected γ-glutamylcysteine syn-
thetase (γ-ECS), the presumed rate-limiting step of GSH
synthesis, as an alternative drug target of TSH2 synthesis
in T. brucei (Figure 3). Knockdown of γ-ECS gene in the
parasite induces cell death and depletion of GSH and TSH2
only after 80% decrease in the enzyme content [79]. The
γ-ECS knockdown cells are rescued from death by adding
external GSH, which elevates the cellular GSH and TSH2
levels [79].
Glutathionesynthetase(GS)hasnotbeenmanipulatedin
trypanosomatids, or in any other organism, perhaps because
it has been considered as a nonrate-limiting step of GSH and
TSH2 biosynthesis. However, DNA microarray analysis of
antimonite-resistant Leishmania tarentolae shows increased
transcription of γ-ECS, GS, and P-glycoprotein A RNAs
[80]. Although it was not evaluated whether increase in
gene transcription correlated with an increase in enzyme
activity,itmaybepossiblethatunderhighGSHdemand(i.e.,
under oxidative stress conditions) GS might exert control of
TSH2 synthesis. On the other hand, ornithine decarboxylase
(ODC) overexpression in T. brucei (the presumed limiting
stepofspermidinesynthesis)causesnochangeinTSH2 levels
[81]. Therefore, ODC does not seem to be a controlling step
of TSH2 synthesis.
Although almost full inhibition (>80%) of gene tran-
scription or activity of any of these enzymes results in par-
asite death, the question remains of how TSH2 metabolism is
aﬀected when the enzymes are less inhibited. For example,
in the therapeutic treatment of patients it is certain that
drugs have to be administered for long periods of time. If
the parasites are not completely cleared from the patient,
disease recurrence and generation of drug-resistant parasites
are possible. The results described above indicate that each
enzyme by itself has low control on TSH2 synthesis and
concentration; therefore, highly speciﬁc and very potent
inhibitors have to be designed in order to attain the required
full activity blockade to aﬀect TSH2 metabolism in these
parasites.10 Journal of Biomedicine and Biotechnology
5. THEORY OF METABOLIC CONTROL ANALYSIS
The metabolic control analysis (MCA) was initially devel-
oped by Kacser and Burns in Scotland [82, 83]a n db y
Heinrich and Rapoport in East Germany [84, 85]. This
analysis establishes a theoretical framework that explains
the results observed with the enzyme overexpression and
downregulation experiments. In addition, it helps to identify
and design experimental strategies for the manipulation of a
given process in an organism (heavy metal hyperaccumula-
tion;increasedproductionofethanol,CO2,lactateoracetate;
or inhibition of a metabolic pathway ﬂux with therapeutic
purposes). MCA rationalizes the quantitative determination
of the degree of control that a given enzyme exerts on
ﬂux and on the concentration of metabolites. Diﬀerent
experimental approaches have been developed to detect and
direct what has to be done and measured, in order to identify
and understand why an enzyme exerts a signiﬁcant or a
negligible control on ﬂux and metabolite concentration in
a metabolic pathway. Thus, the application of this analysis
avoids the “trial and error” experiments for identifying and
manipulating the conceptually wrong “rate-limiting step.”
To understand how a metabolic pathway is controlled
and could be manipulated, its control structure has to be
evaluated. The control structure of a pathway is constituted
by the ﬂux control coeﬃcient (C
J
vi), which is the degree
of control that the rate (v)o fag i v e ne n z y m ei exerts on
ﬂux J; the concentration control coeﬃcient (CX
vi), which
is the degree of control that a given enzyme i exerts on
the concentration of a metabolite (X); and the elasticity
coeﬃcients. The control coeﬃcients are systemic properties
of the pathway that are mechanistically determined by the
elasticity coeﬃcients (εvi
X), which are deﬁned as the degree
of sensitivity of a given enzyme vi (i.e., the enzyme’s ability
to change its rate) when any of its ligands (X: substrate,
products or allosteric modulators) is varied.
The ﬂux control coeﬃcient is deﬁned as
CJ
vi =
dJ
dvi
•
vio
Jo
,( 1 )
in which the expression dJ/dvi describes the variation in
ﬂux (J) when an inﬁnitesimal change is done in the enzyme
i concentration or activity. In practice, the inﬁnitesimal
changes in vi are undetectable, and hence measurable
noninﬁnitesimal changes are undertaken. If a small change
in vi promotes a signiﬁcant variation in J, then this enzyme
exerts an elevated ﬂux control (Figure 4, position 1). In
contrast, if a rather small or negligible change in ﬂux is
observed when vi is greatly varied, then the enzyme does not
exert signiﬁcant ﬂux control (Figure 4, position 2). To obtain
dimensionlessandnormalizedvaluesofC
J
vi thescalingfactor
vio/Jo is applied, which represents the ratio between the
initial values from which the slope dJ/dvi is calculated. If all
C
J
vi of the pathway enzymes and transporters are added up,
the sum comes to one (summation theorem).
The MCA clearly distinguishes between the control
e x e r t e db yag i v e ne n z y m eo nﬂ u x( ﬂ u xc o n t r o lc o e ﬃcient)
and on the metabolite concentration (concentration control
coeﬃcient). Thus, an enzyme can have signiﬁcant control
1
2
F
l
u
x
(
J
)
Enzyme activity
Figure 4: Experimental determination of ﬂux control coeﬃcient.
on a metabolite concentration but not on the pathway ﬂux.
This distinction is important for biotechnology purposes.
On one hand, the use of the rate-limiting step concept
for manipulating metabolic pathways does not make such
diﬀerentiation, which probably has contributed to the many
unsuccessful experiments reported in the literature; on
the other hand, it should be clearly deﬁned whether the
aim of the project is to increase ﬂux and/or a metabolite
concentration since MCA establishes for each aim a diﬀerent
experimental design.
To determine the ﬂux control coeﬃcient of a given
enzyme, small variations in the enzyme content, or prefer-
entially, in activity are required, without altering the rest of
the pathway, and then the changes in ﬂux are determined.
The experimental points are plotted as shown in Figure 4
to calculate the slope at the reference point vio/Jo. This
experiment, apparently easy to perform, has demanded great
intellectual and experimental eﬀort. Several experimental
strategies have been developed to determine C
J
vi:
(i) formation of heterokarionts and heterocygots (classi-
cal genetics),
(ii) titration of ﬂux with speciﬁc inhibitors,
(iii) elasticity analysis,
(iv) mathematical modeling (in silico biology),
(v) in vitro reconstitution of metabolic pathways,
(vi) genetic engineering to manipulate in vivo protein
levels.
5.1. Classicalmendeliangenetics
The arginine biosynthesis in Neurospora crassa was the
ﬁrst metabolic pathway in which ﬂux control coeﬃcients
were experimentally determined by Kacser’s laboratory [86].
This fungus forms multinucleated mycelia that facilitate the
generation of polyploid cells. By mixing diﬀerent ratios of
spores containing genes encoding wild (active) and mutant
(inactive) enzymes of this pathway, it was possible to
generate heterokaryont mycelia with diﬀerent content, and
activity, of four pathway enzymes. The authors built plots ofRafael Moreno-S´ anchez et al. 11
enzymeactivityversusﬂux(seeFigure 4)foracetyl-ornithine
aminotransferase, ornithine transcarbamoylase, arginine-
succinate synthetase, and arginine-succinate lyase. All the
experimental points of these heterokaryonts localized near
to position 2 of Figure 4 with C
J arg
vi = 0.02–0.2 (ﬂux control
by these enzymes was only 2–20%), which indicated that
noneoftheseenzymesexertedsigniﬁcantcontrolonarginine
synthesis. The authors did not determine the remaining ﬂux
control (75%), which might reside in carbamoyl-phosphate
synthetase I (this mitochondrial ammonium-dependent iso-
form can be bound to the mitochondrial inner membrane or
form complexes with ornithine transcarbamoylase [87, 88])
andinmitochondrialcitruline/ornithinetransporter,bothof
which have been proposed as limiting steps, or might be in
the arginine demand for protein synthesis.
Organisms with many alleles of one enzyme may form
homo-and heterozygotes expressing diﬀerent activity levels.
Drosophila melanogaster has three ADH alleles encoding
for isoforms with diﬀerent Vmax. When three natural
homozygotes, a null mutant, and some heterozygotes were
generated, diﬀerent ADH activities were attained but the
ethanol consuming rate did not change (Figure 4, position
2). It was concluded that the ADH ﬂux control was near zero
[89].
5.2. Titrationofﬂuxwithinhibitors(controlof
oxidativephosphorylation)
Oxidative phosphorylation (OXPHOS) is the only pathway
for which speciﬁc and potent inhibitors for many enzymes
and transporters are available. OXPHOS is divided in two
segments (Figure 5): the oxidative system (OS) formed by
substrate transporters (pyruvate, 2-oxoglutarate, glutamate,
glutamate/aspartate, dicarboxylates), Krebs cycle enzymes,
and the respiratory chain complexes; and the phospho-
rylating system (PS) constituted by the ATP/ADP (ANT)
and Pi (PiT) transporters, and ATP synthase. The proton
electrochemical gradient (Δμ−
H
+) connects the two systems.
When the ﬂux (ATP synthesis) is titrated by adding
increasing concentrations of each speciﬁc inhibitor, plots
are generated in which the enzyme activity is progressively
diminishedbyincreasinginhibitorconcentration.Hence,the
C
J
vi value depends on the type of inhibitor used
(a) for irreversible inhibition,
CJ
vi =

−Imax
Jo

dJ
dI

[I]→0
,( 2 )
(b) for simple noncompetitive inhibition,
CJ
vi =

−Ki
Jo

dJ
dI

[I]→0
,( 3 )
(c) for simple competitive inhibition,
CJ
vi =

−Ki

(1+S)/Km

Jo

dJ
dI

[I]→0
,( 4 )
where Jo is the pathway ﬂux in the absence of inhibitor;
Imax, minimal inhibitor concentration to reach maximal ﬂux
inhibition; Ki, inhibition constant; S,s u b s t r a t ec o n c e n t r a -
tion;Km,Michaelis-Mentenconstant;anddJ/dI,initialslope
([I] = 0) of inhibition titration curve.
To estimate ﬂux control coeﬃcients from inhibitor
titration of ADP-stimulated (state 3) respiratory rates (i.e.,
mitochondrial O2 consumption coupled to ATP synthesis),
(2) for irreversible inhibitors was used because researchers
assumed that mitochondrial inhibitors such as rotenone,
antimycin,carboxyatractyloside,andoligomycinwere“pseu-
doirreversible,” due to the enzyme’s high aﬃnity for them.
However, under this assumption ﬂux control coeﬃcients
were usually overestimated [90, 91]. To solve this problem,
G e l l e r i c he ta l .[ 92] developed (5) for noncompetitive
tightly-bound inhibitors and, by using nonlinear regression
analysis, it was possible to include all experimental points
from the titration curve thus increasing accuracy in calcu-
lating C
J
vi:
J =

n

Jo − Ji
2
•En
Co•Jo•Eo
n
n −Co

•Jo −

n•Ji

•En
	
+Ji
E2 +

Kd+I − Eo

•E − Kd•Eo = 0,
(5)
in which Jo and Ji are the respiration ﬂuxes in the nonin-
hibited (E = Eo) and inhibited (E = 0) states; Kd is the
dissociation constant of the enzyme-inhibitor complex, and
n is an empirical component that expresses the relationship
between substrate concentration and the reaction catalyzed
by the enzyme E.
TheanalysisofdatainTable 3 showsthatOXPHOSisnot
controlled by only one limiting step, but the ﬂux control is
rather distributed among several enzymes and transporters.
It is worthnoting thatthe value of the ﬂuxcontrol coeﬃcient
depends on the content of enzyme or transporter, which
variesfromtissuetotissue.PerhapstheATP/ADPtranslocase
in AS-30D hepatoma mitochondria might reach the status of
being the “OXPHOS limiting step” with a C
JOxPhos
ANT = 0.70,
or the Pi transporter in kidney mitochondria [93], or the
ATP/ADP translocase and the respiratory chain complex 3
in liver mitochondria [94], but it should be noted that other
steps also exert signiﬁcant control (Table 3). Although the
distributionofcontrolvariesbetweentissues,theﬂuxcontrol
mainly resides in the PS of organs with high ATP demand
such as the heart (C
JOxPhos
PT+ANT+ATPsynthase = C
JOxPhos
PS = 0.73),
kidney (C
JOxPhos
PS = 0.75; C
JOxPhos
OS = 0.31), and fast-growing
tumors (C
JOxPhos
PS = 0.98). In contrast, in the liver (C
JOxPhos
OS =
0.80; C
JOxPhos
PS = 0.65) and brain (C
JOxPhos
OS = 0.35; C
JOxPhos
PS =
0.41), the control is shared by both systems.
The situation in skeletal muscle appears controversial.
Wisniewski et al. [97] determined that the OXPHOS control
was shared by the PS (C
JOxPhos
PS = 0.62) and the ATP demand
(puriﬁed ATPase). In turn, Rossignol et al. [95]c o n c l u d e d
that the OS exerted the main control (C
JOxPhos
OS = 0.68),
but these authors apparently used low-quality mitochondria
(low respiratory control values that lead to low rates of ATP
synthesis associated with high rates of respiration) that were12 Journal of Biomedicine and Biotechnology
Table 3: Control distribution of oxidative phosphorylation.
Enzyme C
JATP
vi
Rat organ
mitochondria
Speciﬁc
inhibitor
Inhibition
mechanism
Reference
NADH-CoQ-
oxidoreductase (Site 1
of energy
conservation or
Complex I of
respiratory chain)
0.15 Heart (0.5mMpyr +
0.2μMC a 2+)
Rotenone Noncompetitive
tightly bound
[93]
0.26 Heart (10mMpyr +
10mMmal)
[95]
0.31 Kidney (0.5mMpyr +
0.2μMC a 2+)
[93]
0.06 Kidney (10mMpyr +
10mMmal)
[95]
0.06–0.10 Brain (0.05mMpyr +
0.4μMCa 2+)
[91]
0.25 Brain (10mMpyr +
10mMmal)
[95]
0 Tumor (10mMglut +
3mMmal)
[96]
0.27 L i v e r( 1 0m Mp y r+
10mMmal)
[95]
0.13
Skeletal muscle
(10mMpyr +
10mMmal)
[95]
CoQ.cytochrome c
oxidoreductase (Site 2
of energy
conservation or
Complex III of
respiratory chain)
0.01 Heart
Antimycin Noncompetitive
tightly bound
[93]
0.19 Heart [95]
0.02 Kidney [95]
0.05–0.11 Brain [91]
0.02 Brain [95]
0 Tumor [96]
0.43 Liver (5mMSucc +
1μMCa 2+)
[94]
0.07 Liver [95]
0.22 Skeletal muscle [95]
C y t o c h r o m eco x i d a s e
(Site 3 of energy
conservation or
Complex IV of
respiratory chain)
0.11 Heart
Cyanide or azide Noncompetitive
simple
[93]
0.13 Heart [95]
0.04 Kidney [95]
0.02–0.07 Brain [91]
0.02 Brain [95]
0.04 Tumor [96]
0.23 Liver [94]
0.03 Liver [95]
0.20 Skeletal muscle [95]
ATP/ADP transporter
(adenine-nucleotides
or ATP/ADP
transporter, carrier or
exchanger)
0.24 Heart
Carboxy-
atractyloside
(CAT)
Noncompetitive
tightly bound
[93]
0.04 Heart [95]
0 Kidney [93]
0.07 Kidney [95]
0.08 Brain [91]
0.08 Brain [95]
0.60–0.70 Tumor [96]
0.48 Liver [93]
0.01 Liver [93]
0.37
Skeletal muscle
(10mMGlut +
3mMmal)
[97]
0.08 Skeletal muscle [95]Rafael Moreno-S´ anchez et al. 13
Table 3: Continued.
Enzyme C
JATP
vi
Rat organ
mitochondria
Speciﬁc
inhibitor
Inhibition
mechanism
Reference
ATP synthase
0.34 Heart
Oligomycin Noncompetitive
tightly bound
[93]
0.12 Heart [95]
0.32 Kidney [93]
0.27 Kidney [95]
0.09–0.20 Brain [91]
0.26 Brain [95]
0.28 Tumor [96]
0.05 Liver [94]
0.20 Liver [95]
0.10 Skeletal muscle [97]
0.10 Skeletal muscle [95]
Pi transporter
0.15 Heart
Mersalyl Noncompetitive
simple
[93]
0.14 Heart [95]
0.43 Kidney [93]
0.28 Kidney [95]
0.13 Brain [91]
0.26 Brain [95]
0 Tumor [96]
0.05–0.12 Liver [94]
0.26 Liver [95]
0.15 Skeletal muscle [97]
0.08 Skeletal muscle [95]
Pyruvate transporter
0.15 Heart
α-cyano-4-
hydroxy-
cinnamate
Noncompetitive
simple
[95]
0.03 Kidney [95]
0.08 Brain [91]
0.26 Brain [95]
0.21 Liver [95]
0.20 Skeletal muscle [95]
Dicarboxylates
transporter
0.05–0.14 Liver Malate or
butyl-malonate
Competitive
simple
[94]
External ATPase 0.40 Skeletal muscle Puriﬁed ATPase
addition
[94]
not incubated under near physiological conditions (10mM
pyruvate, 10mM malate, 10mM Pi, pH 7.4 in Tris buﬀer),
and the authors incorrectly assumed that rotenone and
antimycin were irreversible inhibitors. It is notorious that in
all works shown in Table 3 at least one of these mistakes is
evident.
There are some inhibitors for enzymes and transporters
from other pathways, but they are not quite speciﬁc and
may aﬀect other sites. Due to the fact that there are no
inhibitorsforeverystepinthesepathways,onlyoneﬂuxcon-
trol coeﬃcient has been determined by inhibitor titration.
Examples of these inhibitors are 6-chloro-6-deoxyglucose
for glucose transporters in bacteria, 2-deoxyglucose for
HPI, iodoacetate for GAPDH [6], 1,4-dideoxy-1,4-imino-
D-arabinitol for glycogen phosphorylase [98], oxalate and
oxamate for LDH, 6-amino nicotinamide for the phosphate
pentose pathway [99], amino-oxyacetate for aminotrans-
ferases and kirureninase (tryptophan synthesis), norvaline
for ornithine transcarbamylase, mercaptopycolinate for PEP
carboxykinase, acetazolamide for carbonic anhydrase, and
isobutyramide for ADH (compiled by Fell [2]).
Potentialusesoftheexperimentalapproach
Mitochondrial pathologies are a heterogeneous group of
metabolic perturbations characterized by morphological
abnormalities and/or OXPHOS dysfunction [100]. Mito-
chondrial DNA analysis has revealed speciﬁc mutations for
some mitochondriopathies. Although the speciﬁc OXPHOS
mutations causing the disease may appear in all tissues,
the functioning of only some of them is altered. The
organ’s sensitivity might be related to the diﬀerent ﬂux14 Journal of Biomedicine and Biotechnology
control coeﬃcients of the mutated enzyme in the diﬀerent
tissues (Table 3) and to their ATP supply dependence from
OXPHOS versus glycolysis.
MCA allows for the analysis of a metabolic ﬂux or
intermediate concentration by focusing either on one step
or by grouping enzymes in blocks or in pathways. Thus,
a comparative analysis of OXPHOS control distribution
reveals that heart, kidney, some fast growing tumors (rat AS-
30D hepatoma, mouse ﬁbrosarcoma, human breast, lung,
thyroid carcinoma, melanoma) [101], and perhaps skeletal
muscle are more susceptible to mitochondrial mutations
in ATP synthase, which is the only PS site with subunits
encoded in the mitochondrial genome. On the other side,
liver and brain might be more susceptible to mitochondrial
mutations of the respiratory chain enzymes (see Table 3).
Considering that the brain is a fully aerobic organ [102],
whereas the liver depends on both OXPHOS (70–80%) and
glycolysis (20–30%) for ATP supply [103], then it can be
postulated that the brain is more sensitive to mutations in
the mitochondrial genome than the liver because subunits of
complexes I, III, and IV are encoded by the mitochondrial
genome.
Titration of ﬂux with speciﬁc inhibitors to determine
the ﬂux control coeﬃcients of OXPHOS has been applied
to intact tumor cells [90]. The results showed that the
ﬂux control resided mainly in site 1 of the respiratory
chain (C
JOxPhos
Sitel = 0.30), whereas the other evaluated sites
exerted a marginal control [90]. This observation could have
therapeutic application if site 1 does not exert control in
healthy cells, leading to less severe side eﬀects.
The use of inhibitors in intact cells to determine control
coeﬃcients might pose two problems: hydrophilic inhibitors
such as carboxyatractyloside (for ANT) and α-cyano-4-
hydroxy-cinammate (for pyruvate transporter) cannot read-
ily enter the cell due to the presence of the plasma membrane
barrier; the other problem is that hydrophobic but slow
inhibitors, such as oligomycin, require long incubation times
to ensure the interaction with the speciﬁc sites. These
problems can be solved by incubating the cells for long
periods of time and taking care of cell viability, for instance,
AS-30D hepatoma cells are fairly resistant to this mechanical
manipulation as they maintain high viability after a lengthy
incubation under smooth orbital agitation of 1h at 37◦C
[90].
5.3. Elasticityanalysis
MCA deﬁnes the elasticity coeﬃcients as
ε
vi
X =
dvi
dX
•
Xo
vio
,( 6 )
whichisadimensionlessnumberthatshowtheratevariation
v of a given enzyme or transporter i when the concentration
of a ligand X (substrate S,p r o d u ctP or allosteric modulator)
is varied in inﬁnitesimal proportions. The elasticity coef-
ﬁcients are positive for those metabolites that increase the
enzyme or transporter rate (substrate or activator), and they
are negative for the metabolites that decrease the enzyme
or transporter rates (product or inhibitor). An enzyme
working, under a steady-state metabolic ﬂux, at saturating
conditions of S or P, is no longer sensitive to changes in these
metabolites. Thus, its elasticity is close to zero (Figure 6,
ε
vi
X = 0).Inturn,anenzymeworkingatSorP concentrations
well below the Michaelis constant (KmS or KmP)i se x p e c t e d
to be highly sensitive to small variations in these metabolites
(Figure 6, ε
vi
X = 1).
The elasticities are intrinsically linked to the actual
enzyme kinetics. If the kinetic parameters of an enzyme
are known (Vmf, Vmr, KmS,a n dKmP), then the enzyme
elasticity for any given metabolite concentration may be
calculated as shown in the following equations.
For substrate,
εvi
s =
−S/Kms
1+S/Kms +P/Kmp
+
1
1 −Γ/Keq
,( 7 )
and for product,
ε
vi
p =
−P/KmP
1+S/Kms +P/KmP
−
Γ/Keq
1 −Γ/Keq
,( 8 )
in which Γ is the mass action ratio, and Keq is the equilib-
rium constant preferentially determined under physiological
conditions.
An enzyme with low elasticity cannot increase (or
decrease) its rate despite large variations in S (or P)
concentration; in consequence, such enzyme exerts a high
ﬂux control. In turn, an enzyme with a high elasticity can
adjust its rate to the variation in S or P concentrations, and
thus it does not interfere with the metabolic ﬂux, exerting
a low ﬂux control. This inverse relationship between the
elasticity and the ﬂux control coeﬃcients is expressed in
a formal equation denominated connectivity theorem. A
metabolic pathway can be divided in two blocks around an
intermediary X: the producing (synthetic, supply) and the
consuming (demand) enzyme blocks of X are i1 and i2,
respectively. Thus, the connectivity theorem for this two-
block system is
C
J
v1
C
J
v2
=−
εv2
X
εv1
X
. (9)
The negative sign of the right part of the equation cancels
with ε
vi1
X , which is negative because X is a product of enzyme
block i1 (Figure 6).
To obtain the ﬂux control coeﬃcients, this approach
requires experimental determination of the elasticity coef-
ﬁcients. How can this be done? Many strategies have been
designed [90, 103–108], but the most used and probably
more trustworthy is that in which the initial pathway
metabolite (So) concentration is varied to increase the
X concentration (any intermediary in the pathway), and
measuring in parallel the variation in ﬂux. Under steady-
state conditions, the ﬂux rate is equal to the rate of end-
product formation (i.e., lactate or alcohol for glycolysis;
oxygen consumption for OXPHOS) and to the rate of any
partial reaction. Then, plots of X versus ﬂux (Figure 7)a r e
generated. The slope, calculated at the reference coordinateRafael Moreno-S´ anchez et al. 15
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Figure 5: Mitochondrial oxidative phosphorylation. ST, oxidizable substrate transporter; KC, Krebs cycle; RC, respiratory chain; (Δμ∼
H
+),
proton electrochemical gradient; ANT, adenine nucleotide translocator; PiT, phosphate transporter; ATP Sint, ATP synthase.
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Figure 6: Elasticity coeﬃcients.
(Xo, Jo)t h a ti se q u i v a l e n tt o( So, vio), yields the elasticity
coeﬃcient of the consuming block of X. In another set
of experiments, an inhibitor is added to block one or
more enzymes after X.T h eX concentration and ﬂux are
determinedandplottedasshowninFigure 7,fromwhichthe
elasticity coeﬃcient of the producing block is calculated.
The ﬂux control coeﬃcients are determined by using the
connectivity theorem and considering that the sum of the
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Figure 7: Experimental determination of the elasticity coeﬃcients
for substrates and products.
control coeﬃcients comes to 1, C1 + C2 = 1 (summation
theorem):
C
J
v1 =
εv2
X
εv2
X −εv1
X
,
C
J
v2 =−
εv1
X
εv2
X −εv1
X
.
(10)
This method for determining C
J
vi using the elasticities
of the two blocks was called double modulation by Kacser
and Burns [83]. Years later, Brand and his group [103, 104]
renamed this method as top-down approach. By applying
the procedure shown in Figure 7 and using (10)f o rd i ﬀerent
metabolites along the metabolic pathway, it is possible
to identify those sites that exert a higher control (which
may be the sites for therapeutic use or biotechnological
manipulation)andthosethatexertanegligiblecontrolunder
a given physiological or pathological situation.
ElasticityanalysishasbeenusedtoevaluatetheOXPHOS
controldistributionintumorcells[90].Almostallstudieson
thissubjecthavebeencarriedoutwithisolatedmitochondria
incubated in sucrose-based medium at 25 or 30◦Co rw i t h
the more physiological KCl-based medium but still at 30◦C
(Table 3). Furthermore, these studies did not consider that
the product, ATP, never accumulates in the living cells,
whichdoesoccurinexperimentswithisolatedmitochondria.
Under such a condition, a steady state in ATP production
can never be reached as in living cells. In other words, the16 Journal of Biomedicine and Biotechnology
distribution of control in mitochondria (Table 3)h a sb e e n
determined in the absence of an ATP-consuming system.
A remarkable exception to this incomplete experimental
design was the work done by Wanders et al. [105], in which
isolatedlivermitochondriawereincubatedwithtwodiﬀerent
ATP-consuming systems (or ADP-regenerating systems):
HK + glucose and creatine kinase (CK) + creatine. Under
this more physiological setting, the OXPHOS ﬂux control
distributed between ANT and the ATP-consuming system;
however, ﬂux control by the other pathway components was
not examined. Therefore, to accurately evaluate OXPHOS
control distribution, mitochondria should be incubated in
the presence of an ATP-consuming system or in their natural
environment (i.e., inside the cell).
The rate of OXPHOS in intact cells is determined from
the rate of oligomycin-sensitive respiration: in the steady
state, the enzyme rates are the same and constant; in
branchedpathwaysthesumofthebranchedﬂuxesequalsthe
ﬂux that supplies the branches. The global elasticity of the
ATP-consuming processes (e.g., synthesis of protein, nucleic
acid, and other biomolecules, as well as ion ATPases to main-
taintheionicgradients,mechanicalactivitysuchasmuscular
contraction or ﬂagellum and cilium movement, and secre-
tion of hormones, digestive enzymes and neurotransmitters)
is estimated by inhibiting ﬂux with low concentrations of
oligomycin or a respiratory chain inhibitor. To determine the
elasticity of the ATP-producing block, ﬂux, and [ATP] are
varied with streptomycin, an inhibitor of protein synthesis
(Figure 7). The elasticity coeﬃcients are calculated from
the initial coordinate slopes (without inhibitors) of each
titration. With this procedure, it has been determined that
the ATP-consuming block exerts a signiﬁcant ﬂux control of
34% [90]. Remarkably, this ﬂux control value obtained in
cells is quite similar to the ﬂux control coeﬃcients of the
ATP-consuming system (HK or CK) reported by Wanders
et al. [105] with isolated mitochondria.
Elasticity analysis by enzyme blocks allows the inclusion
of the end-product demand as another pathway block. The
conclusions obtained from this analysis have formulated the
supply-demand theory [30], which proposes that when ﬂux
is controlled by one block (demand), the concentration of
the end-product is determined by the other block (supply).
The ratio of elasticities determines the distribution of ﬂux
control between supply and demand blocks. For instance,
if ε
Supply
X >ε Demand
X (i.e., demand becomes saturated by
the end-product X, and hence its elasticity is near zero),
then the demand block exerts the main ﬂux control. For
concentration control, at larger εDemand
X − ε
Supply
X ,s m a l l e r
absolute values of both CX
Supply and CX
Demand are attained;
hence, under demand saturation, the supply elasticity fully
governs the magnitude of the variation in the end-product
concentration. On the other hand, when demand increases,
it loses ﬂux control and induces a diminution in the end-
product concentration. In turn, supply gains ﬂux control
and loses concentration control. In the presence of feed-
back inhibition, the system can maintain the end-product
concentration orders of magnitude away from equilibrium
(at a concentration around the K0.5 of the allosteric enzyme).
As mentioned before, the demand is not usually included
in the pathway because it is erroneously thought that it is
not part of it. But then, is it valid to analyze the control
of a metabolite synthesis if its demand is not considered?
When the demand block is not included, it is assumed that
the metabolic pathway produces a metabolite at the same
rate regardless whether the metabolite demand is high or
low. This reasoning is incorrect because a metabolic pathway
indeed responds to changes in the metabolite demand
and, more importantly, a pathway without end-products
consumption reactions is unable to reach a steady state.
Therefore, a metabolic pathway can be divided in supply
and demand blocks. The intermediary X linking the two
blocks is one of the end-products of the producing block
(e.g., pyruvate or lactate or ethanol, and ATP for glycolysis).
The variation in rate of the two blocks in response to
a variation in X can be theoretical or experimentally
determined (Figure 8(a)). It is worth noting that, for this
supply-demand approach, it is not necessary to know the
kinetics of each pathway enzyme because the rate response
of each block reﬂects the global kinetics of all participating
enzymes. When the X concentration is increased, the rate
of the supply block decreases (i) because X is its product
and (ii) because usually an enzyme within this block receives
information from the ﬁnal part of the pathway, decreasing
its rate through feedback inhibition. In turn, the rate of the
demand block increases as X is its substrate.
To better visualize the eﬀect of large rate changes, the
kinetics of both blocks are plotted in a logarithmic scale.
Figure 8(b) shows the kinetics described in Figure 8(a) con-
verted to natural logarithm. The intersection point between
kinetic curves, at which the supply and demand rates are
identical, represents the pathway steady-state ﬂux (in the
Y axis) and end-product concentration (in the X axis).
Since the elasticity is also deﬁned as ε
vi
X = dlnvi/dlnX,
the slope at the intersection point represents the elasticity
of each block towards the intermediary X. Here, the use
of the scalar factor is not necessary because it is included
in the logarithmic equation. With the elasticity coeﬃcients
calculated from plots like those shown in Figure 8, and the
connectivity theorem, the ﬂux control coeﬃcient of each
block is determined. The example in Figure 8(b) shows that
the demand exerts a high ﬂux control (and has low elasticity)
and the supply block exerts low control (and has high
elasticity).
The fact that the demand may exert a high ﬂux con-
trol in metabolite pathways has at least three important
implications: (a) the supply block responds to variations
in the demand (high elasticity); (b) the demand block has
information transfer mechanisms towards the supply block
thatavoidtheunrestrictedintermediaryaccumulationunder
a low demand, particularly when the supply block has
reactions with large Keq (>100; ΔG
◦  > 3Kcalmol −1 at
37◦C); and (c) if the main ﬂux control resides in the demand
block, then the supply block may only exert control on the
intermediaryconcentrationbutnotontheﬂux[30,32].This
lastconclusionexplainswhyitisincorrecttoconsiderthatan
enzyme that controls ﬂux must also control the intermediary
concentration.Rafael Moreno-S´ anchez et al. 17
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Figure 8: (a) Kinetics of the synthesis (supply) and consuming
(demand) blocks of the intermediary X. The kinetic parameters
are from enzymes in tobacco glutathione (GSH) synthesis. X
represents the intermediary concentration, in this case GSH. (b)
Rateplots of thesupplyanddemand blocks in anaturallogarithmic
scale.
Regulatory mechanisms of enzyme activity are modula-
tion of protein concentration by synthesis and degradation,
aswellascovalentmodiﬁcationandvariationinthesubstrate
or product concentrations (which are components of the
pathway). In addition, another regulatory mechanism is the
modulation by molecules that are not part of the path-
way, that is, through allosteric interaction with cooperative
(sigmoidal kinetics) or noncooperative enzymes (hyperbolic
kinetics) (e.g., Ca2+ activates some Krebs cycle dehydro-
genases; citrate inhibits PFK-1; malonyl-CoA inhibits the
mitochondrial transporter of acyl-carnitine/carnitine; or the
initial substrate of a pathway that has not entered the
system). For these last cases, Kacser and Burns [83] proposed
the use of the response coeﬃcient R which is deﬁned by the
following expression:
R
J
M = CJ
vi•ε
vi
M, (11)
where M is the external modulator of the i enzyme. The
response coeﬃcient is dJ/dM•Mo/Jo. If the elasticity of
the sensitive enzyme toward the external eﬀector is also
determined, then it is possible to calculate C
J
vi by using
(11). Unfortunately, due to the experimental complexity
for determining the elasticity coeﬃcient, this coeﬃcient is
often calculated in a theoretical way by using the respective
rate equation (Michaelis-Menten or Hill equations) and the
kinetic parameters Km and Vmax determined by someone
else under optimal assay conditions, which are commonly
far away from the physiological ones. Therefore, for this
theoretical determination of elasticity only the value of
the external modulator concentration is required. It is
convenient to emphasize that the determination of the
ﬂux control coeﬃcients becomes more reliable when they
are calculated from several experimental points (Figure 7),
instead of only one, as occurs with the theoretical elasticity
analysis.
Groen et al. [106] determined the ﬂux control distri-
bution of gluconeogenesis from lactate in hepatocytes by
using both theoretical and experimental elasticity analysis
and the response coeﬃcient. These authors concluded that
gluconeogenesis stimulated by glucagon was controlled by
the pyruvate carboxylase (C
Jglucose
PC = 0.83); in the absence
of this hormone, the control was shared by PC, PYK, ENO-
PGK segment, and TPI-fructose-1,6-biphosphatase segment
[106].
Elasticity analysis has been applied to elucidate the ﬂux
control of ATP-producing pathways in fast-growing tumor
cells. For OXPHOS, this approach showed that respiratory
chain complex I and the ATP-consuming pathways were
the enzymes with higher control (C
J
vi = 0.7) [90]. For
glycolysis, the main ﬂux control (C
J
vi = 0.71) resided in
GLUT + HK reactions because HK is strongly inhibited by
its product G6P despite extensive enzyme overexpression
[107]. Examples of elasticity analysis on other pathways are
photosynthesis [108], ketogenesis [109], serine [110]a n d
threonine synthesis in E. coli [111], glycolysis in yeast [112],
glucose transport in yeast [113], DNA supercoiling [114],
glycogen synthesis in muscle [115], and galactose synthesis
in yeast [116].
In conclusion, the elasticity analysis is the most fre-
quently used method for determining ﬂux control coeﬃ-
cients because it does not need a group of speciﬁc inhibitors
for all the enzymes and transporters of the pathway, neither
does it require knowledge of the inhibitory mechanisms or
kinetic constants. It is only necessary to produce a variation
in the intermediary concentration X by using an inhibitor of
either block or by directly varying the X concentration.
5.4. Pathwaymodeling
In agreement with Fell [2], it seems impossible for a
researcher to analyze one by one the rate equation of each18 Journal of Biomedicine and Biotechnology
enzyme in a metabolic pathway to predict and explain the
system behavior as a whole. To deal with this problem,
in the last three decades some scientists have constructed
mathematical models for some metabolic pathways using
several software programs. Thus, the speciﬁc variation
of a single enzyme activity without altering the rest of
the pathway (Figure 4), which has been an experimentally
diﬃcult task for applying MCA, becomes easier to achieve
with reliable computing models. The term “in silico biology”
has been coined for this approach.
There are two basic types of modeling: (a) structural
modeling and (b) kinetic modeling. The former is related to
thepathwaychemicalreactionstructureanddoesnotinvolve
kinetic information. The use of reactions is based on their
stoichiometries. The information obtained with structural
modeling is the description of the following:
(i) the exact determination of which reactions and
metabolites interact among them;
(ii) the conservation reactions. There are metabolites for
whichtheirsumisalwaysconstantorconserved(e.g.,
NADH + NAD+; NADPH + NADP+; ubiquinol +
ubiquinone;ATP+ADP+AMP;CoA+acetyl-CoA).
The identiﬁcation of conserved metabolites might
not be obvious;
(iii) enzyme groups catalyzing reactions in a given rela-
tionship with another group of enzymes;
(iv) elemental modules, which are deﬁned as the minimal
number of enzymes required to reach a steady state,
which can be isolated from the system (for a review
about structural modeling; see [117]).
Kinetic modeling is more frequently used. In addition
to an appropriate computing program, this approach
requires the knowledge of the stoichiometries, rate
equations, and Keq values of each reaction in the pathway
(or the Vmax in the forward and reverse reactions), as
well as the intermediary concentrations reached under
a given steady state. Some currently used softwares
are Copasi (http://www.copasi.org/tiki-index.php)
based on Gepasi (http://www.gepasi.org/;[ 118]);
Metamodel [119]; WinScamp [120]a n dJ a r n a c[ 121]
(both available at http://www.sys-bio.org/); and PySCeS
(http://pysces.sourcesforge.net/;[ 122]). For other programs
and links, go to http://sbml.org/index.psp.T or e a c ha
steady-state ﬂux, it is necessary to ﬁx the initial metabolite
concentration to a constant value and the irreversible and
constant removal of the end products. Except for the ﬁnal
reactions in which their products have to be removed from
the system, all pathway reactions have to be considered as
reversible, notwithstanding whether they have large Keq
(if there is an irreversible reaction under physiological
conditions, then a reversible rate equation that includes
the Keq suﬃces to maintain the reaction as practically
irreversible). Care should be taken to include the enzyme’s
sensitivity toward its products because this property is
related with the enzyme elasticity and hence with its ﬂux
control; omission of this parameter may very likely lead to
erroneous conclusions.
Itshouldbepointedoutthatthepurposeofkineticmod-
eling is not merely to replicate experimental data but also to
explain them [117]. Thus, pathway modeling is a powerful
tool thatallowsfor(i)thedetection ofthoseproperties ofthe
pathway that are not so obvious to visualize when the indi-
vidual kinetic characteristics of the participating enzymes
are examined; and (ii) the understanding of the biochemical
mechanismsinvolvedinﬂuxandintermediaryconcentration
control. Modeling requires the consideration of all reported
experimental data and interactions that have been described
for the components of a speciﬁc pathway, thus allowing
for the integration of disperse data, discarding irrelevant
facts [84]. Although all models are oversimpliﬁcations of
complex cellular processes, they are useful for the deduction
of essential relationships, for the design of experimental
strategies that evaluate the control of a metabolic pathway,
and for the detection of incompatibilities in the kinetic
parameters of the participating enzymes and transporters,
which may prompt the experimental revision of the most
critical uncertainties.
With the model initially constructed, the simulation
results do not usually concur with the experimental results;
in consequence, the model normally requires reﬁnement, a
point at which the researcher’s thinking and knowledge of
biology plays a fundamental role in modifying the structure
and parameters of the model. The discrepancies observed
between modeling and experimentation unequivocally pin-
point what elements or factors have to be re-evaluated or
incorporated so that the model approximates more closely
reality (i.e., experimental data). The comparison of the
experimentally obtained intermediary concentrations and
ﬂuxes with those obtained by simulation is an appropriate
validating index of the model; this index indicates whether
the model approximation to the physiological situation is
acceptable or whether re-evaluation of the kinetic properties
of some enzymes and transporters and/or incorporation of
other reactions or factors is required.
A reason to why the results obtained by modeling may
substantially diﬀer from the experimental results is that the
kinetic parameters of the pathway enzyme and transporters
and the Keq values used were determined by diﬀerent
research groups, under diﬀerent experimental conditions
and in diﬀerent cell types. Moreover, enzyme kinetic assays
are carried out at low, diluted enzyme concentrations (thus
discarding or ignoring relevant protein-protein interac-
tions), and at optimal (but not physiological) pH and “room
temperature” (which may be far away from the physiological
values). In addition, no experimental information is usually
availableregardingthereactionsreversibilityandtheproduct
inhibition of the enzymes and transporters (particularly for
physiological irreversible reactions, i.e., reactions with large
Keq). With worrisome frequency,the researcherhastoadjust
theexperimentallydeterminedVmandKmvaluestoachieve
a model behavior that acceptably resembles that observed
in the biological system. Apparently, this type of limitations
as well as the sometimes overwhelming amount of kinetic
data necessary for the construction of a kinetic model has
restricted the number of reliable models that can be used for
the prediction of the pathway control structure.Rafael Moreno-S´ anchez et al. 19
Once the kinetic model stability, robustness, struc-
tural and dynamic properties have been evaluated, and
experimentally validated, the model may become a virtual
laboratory in which any parameter or component can be
modiﬁed or replaced and any aspect of the pathway behavior
can be explored within a wide diversity of circumstances or
limits[117].Atthisstage,themodelissuitableforexamining
the pathway regulatory properties and control structure.
Glycolysis in S. bayanus, S. cerevisiae [113, 123, 124],
and Trypanosoma brucei [125, 126] is the metabolic pathway
that has been more extensively modeled. Both cell types
have a very active glycolysis and are fully dependent on
this metabolic pathway for ATP supply, under anaerobiosis
and aerobiosis, respectively. One advantage of modeling
glycolysis in these cell types is that most of the kinetic
parameters used have been experimentally determined by
the same groups under the same experimental conditions.
However, the kinetics of the reverse reactions has not been
determined and thus these authors used KmP and Keq
values reported by others and obtained in other cell types
under rather diﬀerent experimental conditions, or they were
adjusted to improve model ﬁtting.
Nevertheless, the simulation results yielded relevant
information on the control of the glycolytic ﬂux. In both
cases, the enzymes traditionally considered the rate-limiting
steps, HK, ATP-PFK-1, and PYK did not contribute to the
ﬂux control, whereas the main control resided in GLUT
(54% in the parasite and 85–100% in yeast). Under some
conditions,HKmayexertsomecontrol(15%)inS.cerevisiae
and some nonallosteric enzymes such as ALDO, GAPDH,
and PGK may also exert some ﬂux control in T. brucei.
MCA through kinetic modeling has been applied to
several pathways:
(i) glycolysis in erythrocytes [84]i nw h i c hﬂ u xc o n t r o l
distributes between HK (71%) and PFK-1 (29%);
(ii) carbohydrate metabolism during diﬀerentiation in
Dictyostelium discoideum [127] with cellulose syn-
thase (86%) as the main controlling step;
(iii) sucrose accumulation in sugar cane with HK, inver-
tase, fructose uptake, glucose uptake, and vacuolar
sucrose transporter having the most signiﬁcant ﬂux
control [128];
(iv) glycerol synthesis in S. cerevisiae with GAPDH (85%)
as the main control step [129];
(v) penicillin synthesis in Penicillium chrysogenum con-
trolled (75–98%) either by d-(a-aminoadipyl) cys-
teinylvaline synthetase (short incubation times <30
hour) or isopenicillin N. synthetase (long incubation
times > 100h) [130];
(vi) Calvin cycle [131] controlled by GAPDH (50%) and
sedoheptulose-1,7-bisphosphatase (50%);
(vii) threonine synthesis in E. coli controlled by homoser-
ine dehydrogenase (46%), aspartate kinase (28%),
and aspartate semialdehyde dehydrogenase (25%)
[111];
(viii) lysine production in Corynebacterium glutamicum
mainly controlled by aspartate kinase and permease
[132];
(ix) nonoxidativepentosepathwayinerythrocytesmainly
controlled by transketolase (74%) [133];
(x) EGF-induced MAPK signaling in tumor cells con-
trolled by Ras-activation by EGF (21%), Ras dephos-
phorylation (43%), ERK phosphorylation by MEK
(44%), and MEK phosphorylation by RAS (143%)
[13];
(xi) Aspergillus niger arabinose utilization with ﬂux con-
trol shared by arabinose reductase (68%), arabitol
dehydrogenase (17%), and xylulose reductase (14%)
[134];
(xii) glycolysisinL.lactisinwhichseveralendproductsare
generated (lactate, organic acids, ethanol, acetoin)
[135]. Model predictions indicated that ﬂux toward
diacetyl and acetoin (important ﬂavor compounds)
wasmainlycontrolledbyLDHbutnotbyacetolactate
synthetase, the ﬁrst enzyme of this branch.
We modeled the GSH and PCs biosynthesis (Figure 2)
to determine and understand the control structure of the
pathway and thus be able to identify potential sites for
genetic engineering manipulation that might lead to the
generation of improved species in heavy metal resistance
and accumulation. Two models were constructed, one for
higher plants and the other for yeast, both exposed to high
concentrations of Cd
2+ [136]. Due to the similarity in the
results, only the plant results are analyzed below.
An interesting conclusion from the GSH-PCs synthesis
modeling is that control of ﬂux (and GSH concentration)
is shared between the GSH supply and demand under both
unstressed and Cd
2+ exposure conditions (Table 4). This
observation strongly diﬀers from the idea that γ-ECS is the
rate-limitingstep[33–35].Formanyresearchers,theconcept
of γ-ECS being the key controlling step has seemed to be
correctbecause(a)γ-ECSreceivesinformationfromtheﬁnal
part of the pathway, as it is potently inhibited by GSH, the
pathway end-product; and (b) γ-ECS is localized in the ﬁrst
part of the pathway (Figure 2). In addition, GS is usually
more abundant and eﬃcient than γ-ECS [137].
However, in most of the studies on the control of GSH
synthesis, the GSH demand has not been considered. The
GSH synthesis modeling shows that under a physiological
feedback inhibition of γ-ECS by GSH a small increase
in demand increases ﬂux because the GSH concentration
decreases and the γ-ECS inhibition attenuates. In contrast,
if the demand remains constant, then an increase in γ-ECS
activity or content (by overexpression) does not increase ﬂux
becausetheGSHinhibitionisstillthereandoperatesonboth
new and old enzymes. The same pattern is also observed
when HK is overexpressed to increase glycolytic ﬂux since it
isstillinhibitedbyG6P(seeSection 3).Ontheotherhand,γ-
ECS indeed exerts signiﬁcant concentration control on GSH,
which means that a γ-ECS increase results in higher GSH
concentration (Table 4). This last observation demonstrates20 Journal of Biomedicine and Biotechnology
Table 4: Control of GSH and PC synthesis in plants exposed to Cd
2+.
Enzyme 1x γ-ECS + PCS 2.5x γ-ECS + PCS
C
JGSH
vi C
JPC
vi CGSH
vi CPC
vi C
JGSH
vi C
JPC
vi CGSH
vi CPC
vi
γ-ECS 0.58 0.60 0.68 0.76 0.45 0.61 0.70 0.60
GS <0.01 <0.01 0.01 0.01 0.19 <0.01 <0.01 0.97
GS-transferase 0.01 −0.06 −0.07 −0.07 <0.01 <0.01 < −0.01 −0.05
PCS 0.40 0.44 −0.63 −0.56 0.33 0.44 −0.62 0.57
vacuole PC-Cd transporter <0.01 <0.01 <0.01 −1.2 <0.01 <0.01 <0.01 −2.1
C
JGSH
vi ,c o n t r o lc o e ﬃcient of enzyme i in GSH synthesis; C
JPC
vi ,c o n t r o lc o e ﬃcient of enzyme Ei on PCs synthesis; CGSH
vi ,c o n t r o lc o e ﬃcient of enzyme i on
GSHconcentration;CPC
vi ,c ontr olc oeﬃcientofenzymeionPCsconcentration.Anenzymewithanegativeﬂuxcontrolindicatesthatitislocalizedinabranch,
turning aside the principal ﬂux; an enzyme with a negative concentration control indicates that an increase in its activity decreases metabolite concentration.
that an enzyme controlling a metabolite concentration does
not necessarily control the ﬂux.
Cd
2+ exposure promotes a high GSH demand because
signiﬁcant oxidative stress surges, thus causing oxidation of
GSH through GSH peroxidases, and because GSH and PCs
are used for sequestering the toxic metal ion; hence, a higher
GSHconsumingratesetsup.Underthiscondition,modeling
predicted that control was almost equally shared between the
supply and demand blocks, but particularly between γ-ECS
and PCS (see Figure 2). Modeling was also able to explain
why PCS overexpression can have toxic eﬀects on the cell
[36]. An increase in the GSH demand (PCS overexpression)
under high-demand conditions (Cd
2+ stress) leads to GSH
depletion that severely compromises other processes such as
the oxidative stress control and xenobiotic detoxiﬁcation.
The conclusions drawn by this model led us to pro-
pose that, to signiﬁcantly increase the Cd
2+ resistance and
accumulation, γ-ECS and PCS should be simultaneously
overexpressed (Table 4; Figure 9). This particular manipu-
lation promotes an increase in the rate of GSH and PCs
synthesis (determined by the high-to-low transition of their
ﬂux control coeﬃcients) and in the GSH and PCs concen-
trations (determined by their high concentration control
coeﬃcients). The model predicts that a 2-fold increase in
the simultaneous overexpression of γ-ECS and PCS brings
about a 1.9–2.4-fold increase in ﬂux to GSH (JGS)a n d
PCs (JPCS) and in PCs concentration (Figure 9); a 5-fold
overexpression further increases by 4.5–8.1 times the ﬂuxes
and PCs concentration.
This proposed enzyme overexpression should not exceed
the GS and the complex PC-Cd (or GS-Cd-GS) vacuolar
transporters’ maximal activities, in order to keep the cell
away from a severe oxidative stress caused by GSH depletion
or γ-EC accumulation. Indeed, the concentration of GSH
was maintained high and constant although γ-EC accu-
mulated with the simultaneous overexpression (Figure 9).
Furthermore, this enzyme manipulation should avoid the
increase of the PC-Cd and GS-Cd-GS complexes in cytosol
to toxic levels. In other words, excessive enzyme overex-
pression should be avoided, unless this is accompanied by
compensatingoverexpressionofconsumingenzymes(GSfor
γ-ECS overexpression and PCs vacuolar transporters for that
of PCS). In yeasts and plants, Cd
2+ is ultimately inactivated
by the additional interaction with S2− and the subsequent
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Figure 9: Modeled simultaneous overexpression of two controlling
enzymes, one in the supply (γ-glutamylcisteine synthetase, γ-ECS)
and the other in the demand branch (phytochelatin synthase, PCS),
of the glutathione and phytochelatins synthesis pathway in plants.
formation of stable high molecular weight complexes with
PCs, Cd
2+,S 2−,a n dG S H[ 138, 139]. In parallel to the γ-ECS
and PCS overexpression, moderate repression of GSH-S-
transferases,whichcompetefortheavailableGSH(Figure 2),
mayalsopromoteanincreaseinGSHconcentrationandPCs
formation ﬂux [136].
MCA is based on inﬁnitesimal changes in an enzyme or
metabolite concentration. In contrast, gene overexpression
induces large changes in activity; hence, further theoretical
background has been developed for predicting the eﬀect
on ﬂux and metabolite concentrations induced by large
enzyme changes. Such a theoretical background was initially
developed by Small and Kacser [140], who depicted (12)
based on the ﬂux control coeﬃcients to predict the eﬀect
promoted by large changes in enzyme activity:
f
J
Er
j−m =
1
1 −

m
i=j

C
Jo
vi0•

ri −1)/ri)
, (12)
in which f is the ampliﬁcation factor (the ﬂux increase),
and r represents how many times the enzyme is overex-
pressed. To predict the ﬂux changes, promoted by identicalRafael Moreno-S´ anchez et al. 21
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Figure 10: Eﬀect on ﬂux when one or more enzymatic activities
with diﬀerent control coeﬃcients are varied. This ﬁgure represents
an enzyme or group of enzymes in which their CJ
vi sum is indicated
in parenthesis and is modiﬁed by the same r factor. Number 1
represents the reference control, thus if r<1, there is suppression,
whereas r>1 represents overexpression.
overexpression of two enzymes (same r value) with diﬀerent
C
J
vi, the equation is
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. (13)
Figure 10 shows the eﬀect on ﬂux when one or more
enzymes with diﬀerent C
J
vi are changed by the same r factor.
If the sum of C
J
vi of one or more enzymes is less than
0.25, the impact on ﬂux is discrete when the expression
increases 5 folds (which is the most common variation in
the overexpression experiments analyzed in Section 2). But
for a 3-fold overexpression of a group of enzymes, for which
their sum of C
J
vi is more than 0.5, then a signiﬁcant ﬂux
change is achieved. If the sum of C
J
vi is 1, the ﬂux varies in
a linear proportion with the degree of overexpression. It has
to be remarked, however, that the predicted change in ﬂux
(Figure 10) will be valid until certain degree, the limits of
which being determined by the other pathway enzymes that
should stay as noncontrolling steps.
Figure 10 also shows the eﬀect on ﬂux of decreasing
an enzyme activity (third quadrant). This segment plot is
useful when inhibition of pathway ﬂux is being pursued for
therapeutic purposes or for understanding the molecular
basis of the genetic dominance and recessivity. Like in the
enzyme overexpression experiment, only a signiﬁcant eﬀect
on ﬂux is achieved when the enzymes with high C
J
vi values
are inhibited. For an enzyme or group of enzymes with C
J
vi
of 0.25, greater than 80% inhibition has to be attained to
decrease 50% the pathway ﬂux. In this context, it seems
feasible to explain why knockdown of enzymes involved
in TSH2 synthesis has to be almost total to detect an
eﬀect on TSH2 content or to alter functional or pathogenic
properties of the parasites (Section 4.3). The knockdown or
knockout experiments in trypanosomatids suggest that γ-
ECS, TryS, and TryR most probably have low ﬂux control
and concentration-control coeﬃcients since their contents
or activities have to be reduced >80% of the normal levels
to reach changes in intermediary levels or in oxidative stress
handling.
Contrary to the several unsuccessful overexpression
experiments carried out to increase the ﬂux or metabolites
of a metabolic pathway, modeling may allow for a more
focused and appropriate design of experimental strategies of
genetic engineering to increase ﬂux or a given metabolite,
and for selecting drug targets to decrease ﬂux or metabolite
concentration. For these predictions, modeling considers
that overexpression of a controlling enzyme or transporter
may promote ﬂux or metabolite control redistributions.
Thus, a low-control step may become a controlling point
when overexpressing another step and, in consequence, the
predictionshowninFigure 10basedon(11)and(12)ma ybe
inaccurate. By considering the whole pathway components,
modeling is also a powerful tool for predicting the eﬀects
on ﬂux and metabolite concentration of varying an enzyme
activity (by overexpression or drug inhibition).
Modelpredictionstoinhibitapathwayﬂux
Kinetic modeling has been used to identify the ﬂux control-
ling steps in Trypanosoma brucei glycolysis for drug targeting
purposes. Interestingly, modeling has predicted controlling
steps for the parasite pathway diﬀerent from those described
for glycolysis in human host cells [125, 126].
Entamoeba histolytica is the causal agent of human
amebiasis. The parasite lacks functional mitochondria and
has neither Krebs cycle nor OXPHOS enzyme activities.
Therefore, substrate level phosphorylation by glycolysis is
the only way to generate ATP for cellular work [141]. An
important diﬀerence in amebal glycolysis in comparison to
glycolysis in human cells is that it contains the pyrophos-
phate (PPi)-dependent enzymes phosphofructokinase (PPi-
PFK) and pyruvate phosphate dikinase (PPDK), which
replace the highly modulated ATP-PFK and PYK present in
human cells. Moreover, both have been proposed as drug
targets by using PPi analogues (bisphosphonates) [141].
We recently described the construction of a kinetic
model of E. histolytica glycolysis to determine the control
distribution of this energetically important pathway in
the parasite [142]. The model was constructed using the
Gepasi software and was based on the kinetic parameters
determined in the puriﬁed recombinant enzymes [143],
as well as the enzyme activities, ﬂuxes, and metabolite
concentrations found in the parasite. The results of the
metabolic control analysis indicated that HK and PGAM
are the main ﬂux control steps of the pathway (73 and
65%, resp.) and perhaps GLUT. In contrast, the PPi-PFK
and PPDK displayed low ﬂux control (13 and 0.1%, resp.)
because they have overcapacity over the glycolytic ﬂux [142].
The amebal model allowed evaluating the eﬀect on ﬂux of
“inhibiting” the pathway enzymes. The model predicted that22 Journal of Biomedicine and Biotechnology
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Figure 11: Modeled ﬂux behavior when inhibiting pathway
enzymes. The predicted ﬂux when varying the enzyme activity
was obtained using the kinetic model for Entamoeba histolyt-
ica glycolysis [142]. In this case, 100% enzyme activity is the
enzyme activity present in amebal extracts, and 100% ﬂux is
the ethanol ﬂux displayed by amoebae incubated with glucose.
PPi-PFK, PPi-dependent phosphofructokinase; PPDK, pyruvate
phosphate dikinase; PGAM, 2,3 bisphosphoglycerate independent
3-phosphoglycerate mutase.
in order to diminish by 50% the glycolytic ﬂux (and the ATP
concentration; data not shown), HK and PGAM should be
inhibited by 24 and 55%, respectively, or both enzymes by
18% (Figure 11). In contrast, to attain the same reduction
in ﬂux by inhibiting PPi-PFK and PPDK, they should be
decreased >70% (Figure 11). Therefore, the kinetic model
results indicate that HK can be an appropriate drug target
because its speciﬁc inhibition can compromise the energy
levels in the parasite. They also indicate that although PPi-
PFK and PPDK remain as promising drug targets because
of their divergence from the human glycolytic enzymes,
highly potent and very speciﬁc inhibitors should be designed
for these enzymes in order to aﬀect the parasite’s energy
metabolism.
5.5. Invitroreconstitutionofmetabolicpathways
Another experimental approach for determining the enzyme
control coeﬃcients is the in vitro reconstitution of segments
of metabolic pathways. It is recalled that for determining
the ﬂux control coeﬃcient exerted by a given step on a
metabolic pathway the enzyme activity has to be varied,
without altering the other components in the system, and
the ﬂux variations are to be measured (Figure 4). Such an
experiment can be readily made if a pathway is reconstituted
with puriﬁed enzymes. Some advantages of this approach
are that the pathway structure is known, in which the com-
ponents concentration may be manipulated and analyzed
separately, and the enzyme eﬀectors can be assayed. As the
system composition is strictly controlled, the results may
be highly reproducible. The main disadvantage is that the
enzyme concentrations in the assays are diluted and thus
the enzyme interactions are not favored. If this interaction is
important for activity, the in vitro reconstitution may limit
the extrapolation to the metabolic pathway inside the cell.
There are not many studies describing this type of
experiments, most probably due to the fact that for applying
MCA the pathway must be working under steady-state
conditions. In a reconstituted system, only a quasi steady
state may be reached because there is net substrate, and
cofactors consumption, as well as product accumulation,
since it is diﬃcult to attain a constant substrate supply and
release of products.
One of the ﬁrst experimental reports on control coeﬃ-
cientdeterminationinareconstitutedsystemwascarriedout
fortheupperglycolyticsegmentwiththecommerciallyavail-
able rabbit muscle HK, HPI, PFK-1, ALDO, and TPI [144].
Each enzyme was separately titrated and the ﬂux variation to
glycerol-3-phosphate (by coupling the reconstituted system
to an excess of α-GPDH) was measured in the presence of
CK to maintain the ATP concentration constant. The ﬂux
controlcoeﬃcientsweredeterminedasdescribedinFigure 4.
The results showed that PFK-1 and HK exerted the main ﬂux
control (65% and 20%, resp.), whereas the remaining 15%
resided in the other enzymes. These authors observed that
the addition of F1,6BP, a PFK-1 activator slightly diminished
the ﬂux control exerted by PFK-1 and increases that of
HK. The validation of the summation theorem was also
demonstrated in this work [144].
The lower glycolytic segment has also been reconsti-
tuted with commercial enzymes for determining the ﬂux
control coeﬃcients [145]. The results showed that ﬂux was
mainly controlled by PYK (60–100%), although under some
conditions control was shared with PGAM; ENO did not
contribute to the ﬂux control.
Another important limitation of the reconstitution
experiments is that the commercial availability of the
puriﬁed enzymes from the same organism is restricted
or inexistent. However, by using the information from
the genome sequence projects and the recombinant DNA
technology, it is now possible to access all the enzyme
genes from a metabolic pathway in the same organism, thus
facilitating their cloning, overexpression, and puriﬁcation.
With this strategy, we cloned, overexpressed, and puriﬁed
the 10 glycolytic enzymes of Entamoeba histolytica [143]f o r
studying the ﬂux control distribution in this organism by
using kinetic modeling [142] and pathway reconstitution.
The reconstitution experiments of the lower amebal
glycolytic segment, under near physiological conditions of
pH, temperature, and enzyme activity (Figure 12) showed
that PGAM and, to a lesser extent, PPDK exert the main
ﬂuxcontrol(theseamebalenzymesaregeneticallyandkinet-
ically diﬀerent from their human counterparts) with ENO
exhibiting negligible control [143]. In turn, reconstitution of
the upper amebal glycolytic segment has revealed that HK
and, to a much lesser extent HPI, PPi-PFK, and ALD, exerted
the main ﬂux control, with TPI having negligible control
[146]. These results strongly correlate with the enzyme
catalytic eﬃciencies previously reported [143], in which HK
is highly sensitive to AMP inhibition, ALD, and PGAMRafael Moreno-S´ anchez et al. 23
have the lowest catalytic eﬃciencies among the glycolytic
enzymes, leading to high ﬂux control coeﬃcients and thus
becoming suitable candidates for therapeutic intervention.
The reconstitution results also agree with the pathway
modeling predictions previously analyzed (Section 5.4), in
which HK and PGAM are two of the main controlling steps
[142].
The in vitro reconstitution experiments are also useful
for studying the eﬀect on control redistribution of an
enzyme modulation that is particularly diﬃcult to manage
in vivo; the main controlling steps identiﬁed with the
reconstitution experiments should be further analyzed with
other experimental strategies such as elasticity analysis in the
in vivo systems.
5.6. Geneticengineeringtomanipulatetheinvivo
proteinlevels
This experimental approach for determining the control
coeﬃcients could be part of the genetic approach analyzed
in Section 5.1, but it was separated due to its recent
methodological development and because it actually belongs
to the molecular genetics rather than to the Mendelian
genetics.
5.6.1. Repressionofgeneexpression
This approach is based on the in vivo modulation of the
enzyme levels using the RNA antisense technology. There
are at least three strategies to inhibit gene expression: (a)
the use of single stranded antisense oligonucleotides, which
form a double stranded RNA that might be degraded by
RNAse H; (b) target RNA degradation with catalytically
active oligonucleotides, known as ribozymes that bind to
their speciﬁc RNA; and (c) RNA degradation using siRNAs
(21–23 nucleotides) [147].
The RNA antisense technology was applied for con-
trol coeﬃcient determination of the ribulose-bisphosphate-
carboxylase (Rubisco) that ﬁxes CO2 in the plant Calvin
cycle. This enzyme considered the rate-limiting step of the
Calvincycleandofthewholephotosyntheticprocess,despite
itshighconcentration(4mM)inthechloroplastsstromathat
compensates its low catalytic eﬃciency.
Attempts to make Rubisco a nonlimiting step, either by
modifying its catalytic eﬃciency or by overexpressing it,
have been unsuccessful. Stitt et al. [148] determined the
C
Jphotosynthesis
rubisco of tobacco plants by decreasing its activity with
DNA antisense. The plants were transformed with DNA
antisense against the mRNA of the enzyme’s small subunit,
thus promoting its degradation. For Calvin cycle enzymes,
the pleiotropic eﬀects were minimal. The results showed that
Rubisco may indeed be the photosynthesis limiting step with
a C
Jphotosynthesis
rubisco = 0.69–0.83 when plants are exposed to high
illumination (1050μmol quanta m−2s−1), high humidity
(85%), and low CO2 concentrations (25Pa). However,
this ﬂux control decreases to 0.05–0.12 under moderate
illumination or high CO2 levels [148]. Unfortunately, the
authors did not determine the control coeﬃcients of the
other pathway enzymes or the branches ﬂuxes which may be
signiﬁcant.
As described in Section 5.4, the results of the T. brucei
glycolysis modeling indicated that GLUT was the main ﬂux
control step (C
J
GLUT ∼ 50%), [125, 126]. This model pre-
dicted a large overcapacity for HK, PFK-1, ALDO, GAPDH,
PGAM, ENO, and PYK over the glycolytic ﬂux leading to low
ﬂux control coeﬃcients [125, 126]. To validate the modeling
results, the concentrations of HK, PFK-1, PGAM, ENO,
and PYK were changed with siRNAs in growing parasites
[149]. These knockdown expression experiments showed
overcapacity of HK and PYK over the ﬂux, although at lower
levels than predicted by the model. A good correlation for
PGAM and ENO was obtained between model predictions
and experimental results. However, a large diﬀerence (9
folds) was obtained for PFK-1. This discrepancy is perhaps
related to pleiotropic eﬀects of PFK-1 downregulation, as
these mutants also displayed diminution in the activities
of other enzymes (HK, ENO, and PYK). The combination
of these two approaches, in silico modeling and in vivo
experimentation, is complementary: on one hand, modeling
identiﬁes the enzymes (out of 19 that contain the model)
that display the highest ﬂux control coeﬃcients, whereas in
vivo experimentation validates the accuracy of the model to
establish predictions about the pathway’s behavior.
5.6.2. Finetuningofcellularproteinexpression
The knockdown experiments described above usually yield
only two experimental points of the plot shown in Figure 4:
the wild-type and the knockdown strain protein levels
or enzyme activities. Thus, with such an approach high
levels of inhibition (>80%) are mostly analyzed, whereas
intermediate levels of downregulation (if obtained) are
generally overlooked. Therefore, knockdown experiments
arenotveryusefultoobtainthecompletesetofexperimental
data(aboveandbelowthewild-typelevelsofenzymeactivity
withthecorrespondingﬂux)fordeterminingreliablecontrol
coeﬃcients.
A strategy to determine ﬂux control coeﬃcients
from several protein levels has been developed by us-
ing adenovirus-mediated glucose-6-phosphatase (G6Pase)
overexpression under the control of the cytomegalovirus
promoter in rat hepatocytes. A 2-fold G6Pase overexpression
did not alter C
Glycolysis
G6Pase or C
Glycolysis
GK (GK, glucokinase).
However, if G6Pase is overexpressed by 4 folds, then
C
Glycogen-synthesis
GK diminished from 2.8 to 1.8 and there was
a 35% lowering in glycogen synthesis [150]. However, this
approachallowstitrationofﬂuxonlyabovethebasalenzyme
activities found in the cell, but not below.
These experimental inconveniences have been circum-
vented by using inducible gene expression systems based in
thelac,Lambda,nisin,GAL,tetracycline,andotherinducible
promoters, in bacteria and yeast [151, 152]. However, a
problem frequently encountered with inducible promoters is
that a steady-state of protein expression is diﬃcult to attain
[151, 152].24 Journal of Biomedicine and Biotechnology
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Figure 12: Determination of ﬂux control coeﬃcients in an in vitro reconstitution of the ﬁnal section of Entamoeba histolytica glycolysis.
Enzymatic assay with the three recombinant enzymes from the ameba: EhPGAM, EhENO, and EhPPDK. LDH, commercial lactate
dehydrogenase. The ﬂux control coeﬃcient was determined at the ∗marked position. 2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate.
Modiﬁed from [143].
Recently, Jensen and Hammer described the design
of synthetic promoter libraries (SPL), in particular for
L. lactis metabolic optimization [153]. These promot-
ers maintain constant the array of the known consen-
sus sequences for L. lactis gene transcription (−10 and
−35 boxes), while the nucleotide sequence between these
boxes (a spacer sequence of 17 ± 1bp) is randomized,
thus producing a set of promoters with diﬀerent tran-
scriptional strength. These promoter libraries allow the
transcription and protein expression several folds above
and below the wild-type levels of enzyme activity [153],
thus enhancing the usefulness of this approach for MCA
studies.
The control distribution of glycolysis in E. coli and L.
lactis, as discussed in Section 3.2 [17, 24, 27, 151], has been
determined by using the SPL technology. SPL for yeast,
mammalian and plant cells are also under development
[151, 152]. Certainly, the advances in genetic engineer-
ing in combination with MCA allow better experimental
designs for metabolic optimization of micro-organisms of
biotechnological interest.Rafael Moreno-S´ anchez et al. 25
Concludingremarks
(1) The frequently recurred idea of manipulating the
key enzyme or rate-limiting step (a concept based
on a qualitative and rather intuitive background)
to change metabolism is incorrect. As MCA has
demonstrated,ﬂuxcontrolissharedbymultiplesteps
and it is not usually localized in only one step.
MCA determines quantitatively the control that a
given enzyme exerts on the ﬂux and on intermediary
concentration and helps to explain why an enzyme
does or does not exert control.
(2) A metabolic pathway is manipulated to change the
rate of the end-product formation (i.e., the ﬂux) or
the concentration of a relevant intermediary. As it is
demonstrated in many unsuccessful experiments, it
is not enough to overexpress one enzyme (the rate-
limiting step) or many arbitrarily selected sites of
the pathway. MCA proposes an initial experimental
analysis that determines the structural control of
the pathway and identiﬁes the sites (enzymes and
transporters) with higher control coeﬃcients values
(i.e., targets to be manipulated). For example, if there
is a system composed of six enzymes and three of
t h e mh a v eﬂ u xc o n t r o lc o e ﬃcients with values of
0.2 or higher and the other three with values of
0.1 or lower, the three enzymes with high control
coeﬃcients must be overexpressed (if a ﬂux increase
is desired) or repressed (if ﬂux inhibition is the
objective) and not only one of them. If one of the
selected enzymes is strongly inhibited by its product
or has allosteric inhibition, the overexpression of
this enzyme might not be enough to increase the
ﬂux, as it may also be necessary to moderately vary
the product and allosteric modulator consuming
enzymes.
(3) If the aim of the researcher is a metabolite con-
centration increase, which is not the end product
of the pathway, MCA suggests the overexpression
of those enzymes or transporters in the supply
block with the highest control coeﬃcients and/or the
repression of those enzymes in the demand block
with the highest control coeﬃcients. These manip-
ulations may become complicated if the metabolite
of interest has allosteric interactions with enzymes
and transporters (inhibition and activation) of both
the supply and demand blocks. It is recalled that
ethanol production in yeast and lactate and acetate
production in lactobacteria do not increase by
overexpressing PFK-1, an allosteric enzyme and the
presumed rate-limiting step of glycolysis. In fact,
the ﬂux was diminished with an excessive PFK-
1 overexpression. However, the analysis of these
results reveals that the F1,6BP concentration is
indeed increased many times over the control level.
Another strategy for eliminating the feedback inhi-
bition might be the introduction of mutations on
the enzymes that are closer to the metabolite of
interest.
ABBREVIATIONS
ADH: alcohol dehydrogenase
CK: creatine kinase
ENO: enolase
GAPDH: glyceraldehyde-3 phosphate dehydrogenase
HPI: hexose phosphate isomerase
LDH: lactate dehydrogenase
PDC: pyruvate decarboxylase
PGK: phosphoglucokinase
PGAM: phosphoglycerate mutase
TPI: triose phosphate isomerase
PPi-PFK: pyrophosphate-dependent phosphofructokinase
α-GPDH: α-glycerophosphate dehydrogenase
F6B: fructose-6-phosphate
F1,6BP: fructose-1,6-bisphosphate
G1P: glucose-1-phosphate
G6P: glucose-6-phosphate
GSH: reduced glutathione
γ-EC: γ-glutamylcysteine
MCA: metabolic control analysis
siRNA: small interfering RNA.
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